UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended November 30, ~~2021.~~2022.

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission file number

0-17988

Neogen Corporation

(Exact name of registrant as specified in its charter)


Michigan		38-2367843
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification Number)

620 Lesher Place

Lansing, Michigan 48912

(Address of principal executive offices, including zip code)

(517)

372-9200

(Registrant’s telephone number, including area code)

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:


Title of each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.16 par value per share	NEOG	NASDAQ Global Select Market

N/A

(Former name, former address and former fiscal year, if changed since last report)

~~Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐~~

~~Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒~~

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T

(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YES

☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule

12b-2

of the Exchange Act.


~~Large accelerated filer~~	☒	~~Accelerated filer~~	☐

~~Non-accelerated~~Large accelerated filer	☐ ☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller Reporting Company	☐
Emerging growth company
~~Emerging growth company~~	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act): YES ☐ NO

☒

As of November 30, ~~2021~~2022 there were ~~107,768,342~~216,154,283 shares of Common Stock outstanding.

NEOGEN CORPORATION AND SUBSIDIARIES

TABLE OF CONTENTS


		Page No.
PART I. FINANCIAL INFORMATION

Item 1.	Interim Consolidated Financial Statements (unaudited)		2

	Consolidated Balance Sheets – November 30, ~~2021~~2022 and May 31, ~~2021~~2022		2

	Consolidated Statements of Income (Loss) – Three and six months ended November 30, ~~2021~~2022 and ~~2020~~2021		3

	Consolidated Statements of Comprehensive Income (Loss) – Three and six months ended November 30, ~~2021~~2022 and ~~2020~~2021		4

	Consolidated Statements of Equity – Three and six months ended November 30, ~~2021~~2022 and ~~2020~~2021		5

	Consolidated Statements of Cash Flows – Six months ended November 30, ~~2021~~2022 and ~~2020~~2021		6

	Notes to Interim Consolidated Financial Statements – November 30, ~~2021~~2022		7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		1924

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		2736

Item 4.	Controls and Procedures		2736

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings		2837

Item 6. 1A.	~~Exhibits~~Risk Factors		2837
Item 6.	Exhibits		38

SIGNATURES			2939

	CEO Certification

	CFO Certification

	Section 906 Certification

PART I – FINANCIAL INFORMATION

Item 1. Interim Consolidated Financial Statements

Neogen Corporation and Subsidiaries

Consolidated Balance Sheets (unaudited)

(in thousands, except share and

per share amounts)


	November 30,			May 31,
	2021			2021			November 30, 2022			May 31, 2022
Assets
Current Assets
Cash and cash equivalents	$	51,119		$	75,602		$	100,000		$	44,473
Marketable securities		338,130			305,485			176,338			336,578
Accounts receivable, less allowance of $1,500 and $1,400 at November 30, 2021 and May 31, 2021, respectively		92,498			91,823
Accounts receivable, net of allowance of $1,950 and $1,650								142,711			99,674
Inventories		107,086			100,701			136,069			122,313
Prepaid expenses and other current assets		22,371			17,840			88,215			23,760

Total Current Assets		611,204			591,451			643,333			626,798
Net Property and Equipment		100,863			100,453			148,170			110,584
Other assets
Other Assets
Right of use assets		2,171			2,477			3,707			3,184
Goodwill		142,613			131,476			2,122,397			142,704
Other non-amortizable intangible assets		15,359			15,545			15,216			15,397
Amortizable intangible and other assets, net of accumulated amortization of $51,012 and $53,462 at November 30, 2021 and May 31, 2021, respectively		93,706			76,771
Amortizable intangible and other assets, net of accumulated amortization of $78,046 and $55,416								1,626,514			92,106
Other non-current assets		2,018			2,019			3,905			2,156

Total Assets	$	967,934		$	920,192		$	4,563,242		$	992,929

Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable	$	34,222		$	23,900		$	79,251		$	34,614
Accrued compensation		9,636			11,251			15,014			11,123
Income taxes		0			1,848
Income tax payable								9,049			2,126
Accrued interest								13,974			—
Deferred revenue								5,083			5,460
Other accruals		18,815			16,600			30,187			24,521

Total Current Liabilities		62,673			53,599			152,558			77,844
Deferred Income Taxes		21,829			21,917
Other Non-Current Liabilities		17,956			4,299
Deferred Income Tax Liability								364,252			17,011
Non-current debt								923,962			—
Other non-current liabilities								16,207			10,700

Total Liabilities		101,204			79,815			1,456,979			105,555
Commitments and Contingencies (note 10)		0			0
Commitments and Contingencies (note 12)
Equity
Preferred stock, $1.00 par value, 100,000 shares authorized,NaN issued and outstanding		0			0
Common stock, $0.16 par value, 120,000,000 shares authorized, 107,768,342 and 107,468,304 shares issued and outstanding at November 30, 2021 and May 31, 2021, respectively		17,243			17,195
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding								—			—
Common stock, $0.16 par value, 315,000,000 shares authorized, 216,154,283 and 107,801,094 shares issued and outstanding at November 30, 2022 and May 31, 2022, respectively								34,584			17,248
Additional paid-in capital		304,959			294,953			2,560,898			309,984
Accumulated other comprehensive loss		(24,235	)		(11,375	)		(40,498	)		(27,769	)
Retained earnings		567,509			539,604			551,279			587,911

Total Stockholders’ Equity		865,476			840,377			3,106,263			887,374

Total Liabilities and Stockholders’ Equity	$	967,934		$	920,192		$	4,563,242		$	992,929

See notes to interim consolidated financial statements.

Table of Contents

Neogen Corporation and Subsidiaries

Consolidated Statements of Income (Loss) (unaudited)

(in thousands, except per share amounts)

Three Months Ended

Six Months Ended


November 30,

November 30,


2021

2020

2021

2020

Revenues

Product revenues
   $ 106,111    $ 92,537 $ 210,124    $ 180,472
Service revenues
   24,406    22,463 48,698    43,853






Total Revenues
   130,517    115,000 258,822    224,325
Cost of Revenues

Cost of product revenues
   56,374    49,275 111,100    95,870
Cost of service revenues
   13,549    12,511 27,120    24,939






Total Cost of Revenues
   69,923    61,786 138,220    120,809






Gross Margin
   60,594    53,214 120,602    103,516
Operating Expenses

Sales and marketing
   21,188    17,729 41,743    34,245
General and administrative
   22,605    12,184 35,988    23,197
Research and development
   4,332    4,056 8,657    7,934






Total Operating Expenses
   48,125    33,969 86,388    65,376






Operating Income
   12,469    19,245 34,214    38,140
Other Income (Expense)

Interest income
   224    555 427    1,277
Other income (expense)
   235    (465 ) 14    (272 )






Total Other Income
   459    90 441    1,005






Income Before Taxes
   12,928    19,335 34,655    39,145
Provision for Income Taxes
   2,100    3,450 6,750    7,400






Net Income
   $ 10,828    $ 15,885 $ 27,905    $ 31,745






Net Income Per Share

Basic
   $ 0.10    $ 0.15 $ 0.26    $ 0.30






Diluted
   $ 0.10    $ 0.15 $ 0.26    $ 0.30






Weighted Average Shares Outstanding


Basic
   107,641    106,258 107,565    106,044
Diluted
   108,122    106,808 108,099    106,600


	Three Months Ended November 30,						Six Months Ended November 30,
	2022			2021			2022			2021
Revenues
Product revenues	$	203,317		$	106,111		$	310,109		$	210,124
Service revenues		26,716			24,406			52,273			48,698

Total Revenues		230,033			130,517			362,382			258,822
Cost of Revenues
Cost of product revenues		102,530			56,374			157,971			111,100
Cost of service revenues		14,964			13,549			29,602			27,120

Total Cost of Revenues		117,494			69,923			187,573			138,220

Gross Margin		112,539			60,594			174,809			120,602
Operating Expenses
Sales and marketing		36,348			21,188			59,731			41,743
General and administrative		77,001			22,605			104,945			35,988
Research and development		6,846			4,332			11,727			8,657

Total Operating Expenses		120,195			48,125			176,403			86,388

Operating Income (Loss)		(7,656	)		12,469			(1,594	)		34,214
Other Income (Expense)
Interest income		553			246			1,523			455
Interest expense		(20,545	)		(22	)		(20,547	)		(28	)
Other income (expense)		(6,443	)		235			(6,814	)		14

Total Other Income (Expense)		(26,435	)		459			(25,838	)		441

Income (Loss) Before Taxes		(34,091	)		12,928			(27,432	)		34,655
Provision for Income Taxes		7,750			2,100			9,200			6,750

Net Income (Loss)	$	(41,841	)	$	10,828		$	(36,632	)	$	27,905

Net Income (Loss) Per Share
Basic	$	(0.19	)	$	0.10		$	(0.23	)	$	0.26
Diluted	$	(0.19	)	$	0.10		$	(0.23	)	$	0.26
Weighted Average Shares Outstanding
Basic		216,134			107,641			161,690			107,565
Diluted		216,134			108,122			161,690			108,099

See notes to interim consolidated financial statements.

Table of Contents

Neogen Corporation and Subsidiaries

Consolidated Statements of Comprehensive Income (Loss) (unaudited)

(in thousands)

Three Months Ended

Six Months Ended


November 30,

November 30,


2021

2020

2021

2020

Net income
   $ 10,828 $ 15,885 $ 27,905 $ 31,745
Other comprehensive income (loss), net of tax:

foreign currency translations
   (7,649 ) 938 (12,272 ) 5,059
Other comprehensive loss, net of tax:

unrealized loss on marketable securities
   (382 ) (317 ) (588 ) (436 )


Total comprehensive income
   $ 2,797 $ 16,506 $ 15,045 $ 36,368


	Three Months Ended November 30,						Six Months Ended November 30,
	2022			2021			2022			2021
Net income (loss)	$	(41,841	)	$	10,828		$	(36,632	)	$	27,905
Foreign currency translations		1,102			(7,649	)		(10,031	)		(12,272	)
Unrealized gain (loss) on marketable securities, net of tax		154			(382	)		(270	)		(588	)
Unrealized loss on derivative instruments, net of tax		(2,428	)		—			(2,428	)		—

Total comprehensive income (loss)	$	(43,013	)	$	2,797		$	(49,361	)	$	15,045

See notes to interim consolidated financial statements.

Table of Contents

Neogen Corporation and Subsidiaries

Consolidated Statements of

Equity (unaudited)

(in thousands)

Accumulated


Additional

Other


Common Stock

Paid-in

Comprehensive

Retained


Shares

Amount

Capital

Income (Loss)

Earnings

Total

Balance, June 1, 2021


107,468


$
17,195


$
294,953


$
(11,375
)

$
539,604


$
840,377

Exercise of options and share-based compensation expense
   6    1    1,838    —   —      1,839
Issuance of shares under employee stock purchase plan
   19    3    896    —   —      899
Net income for the three months ended August 31, 2021
   —      —      —      —   17,077    17,077
Other comprehensive loss for the three months ended August 31, 2021
   —      —      —      (4,829 ) —      (4,829 )










Balance, August 31, 2021


107,493


$
17,199


$
297,687


$
(16,204
)

$
556,681


$
855,363

Exercise of options and share-based compensation expense
   275    44    7,272    —   —      7,316
Net income for the three months ended November 30, 2021
   —      —      —      —   10,828    10,828
Other comprehensive loss for the three months ended November 30, 2021
   —      —      —      (8,031 ) —      (8,031 )










Balance, November 30, 2021


107,768



17,243



304,959


$
(24,235
)

$
567,509


$
865,476











Balance, June 1, 2020


105,892


$
16,943


$
249,221


$
(19,709
)

$
478,722


$
725,177

Exercise of options and share-based compensation expense
   172    28    5,811    —   —      5,839
Issuance of shares under employee stock purchase plan
   18    3    665    —   —      668
Net income for the three months ended August 31, 2020
   —      —      —      —   15,860    15,860
Other comprehensive income for the three months ended August 31, 2020
   —      —      —      4,002 —      4,002










Balance, August 31, 2020


106,082


$
16,974


$
255,697


$
(15,707
)

$
494,582


$
751,546

Exercise of options and share-based compensation expense
   406    64    9,279    —   —      9,343
Net income for the three months ended November 30, 2020
   —      —      —      —   15,885    15,885
Other comprehensive income for the three months ended November 30, 2020
   —      —      —      621 —      621










Balance, November 30, 2020


106,488



17,038



264,976



(15,086
)

510,467



777,395


					Additional		Accumulated Other
	Common Stock				Paid-in		Comprehensive			Retained
	Shares		Amount		Capital		Loss			Earnings			Total
Balance, June 1, 2022		107,801	$	17,248	$	309,984	$	(27,769	)	$	587,911		$	887,374
Exercise of options and share-based compensation expense		4		1		1,904		—			—			1,905
Issuance of shares under employee stock purchase plan		33		5		862		—			—			867
Net income for the three months ended August 31, 2022		—		—		—		—			5,209			5,209
Other comprehensive loss for the three months ended August 31, 2022		—		—		—		(11,557	)		—			(11,557	)

Balance, August 31, 2022		107,838	$	17,254	$	312,750	$	(39,326	)	$	593,120		$	883,798
Exercise of options and share-based compensation expense		46		7		2,630		—			—			2,637
Issuance of shares for 3M transaction		108,270		17,323		2,245,518								2,262,841
Net loss for the three months ended November 30, 2022		—		—		—		—			(41,841	)		(41,841	)
Other comprehensive loss for the three months ended November 30, 2022		—		—		—		(1,172	)		—			(1,172	)

Balance, November 30, 2022		216,154	$	34,584	$	2,560,898	$	(40,498	)	$	551,279		$	3,106,263


							Accumulated
					Additional		Other
	Common Stock				Paid-in		Comprehensive			Retained
	Shares		Amount		Capital		Loss			Earnings		Total
Balance, June 1, 2021		107,468	$	17,195	$	294,953	$	(11,375	)	$	539,604	$	840,377
Exercise of options and share-based compensation expense		6		1		1,838		—			—		1,839
Issuance of shares under employee stock purchase plan		19		3		896		—			—		899
Net income for the three months ended August 31, 2021		—		—		—		—			17,077		17,077
Other comprehensive loss for the three months ended August 31, 2021		—		—		—		(4,829	)		—		(4,829	)

Balance, August 31, 2021		107,493	$	17,199	$	297,687	$	(16,204	)	$	556,681	$	855,363
Exercise of options and share-based compensation expense		275		44		7,272		—			—		7,316
Net income for the three months ended November 30, 2021		—		—		—		—			10,828		10,828
Other comprehensive loss for the three months ended November 30, 2021		—		—		—		(8,031	)		—		(8,031	)

Balance, November 30, 2021		107,768	$	17,243	$	304,959	$	(24,235	)	$	567,509	$	865,476

See notes to interim consolidated financial statements.

Table of Contents

Neogen Corporation and Subsidiaries

Consolidated Statements of Cash Flows (unaudited)

(in thousands)

Six Months Ended


November 30,


2021

2020

Cash Flows From Operating Activities

Net Income
   $ 27,905 $ 31,745
Adjustments to reconcile net income to net cash from operating activities:

Depreciation and amortization
   11,511 9,523
Share-based compensation
   3,438 3,192
Change in operating assets and liabilities, net of business acquisitions:

Accounts receivable
   (1,500 ) 6,662
Inventories
   (6,929 ) 4,063
Prepaid expenses and other current assets
   (3,709 ) (2,080 )
Accounts payable, accruals and other changes
   10,341 (5,581 )


Net Cash From Operating Activities
   41,057 47,524
Cash Flows For Investing Activities

Purchases of property, equipment and other
non-current
intangible assets
   (5,235 ) (11,092 )
Proceeds from the sale of marketable securities
   197,941 309,030
Purchases of marketable securities
   (230,586 ) (308,524 )
Business acquisitions, net of cash acquired
   (26,864 ) (2,350 )


Net Cash For Investing Activities
   (64,744 ) (12,936 )
Cash Flows From Financing Activities

Exercise of stock options and issuance of employee stock purchase plan shares
   6,619 12,658


Net Cash From Financing Activities
   6,619 12,658
Effect of Foreign Exchange Rates on Cash
   (7,415 ) 352


Net Increase (Decrease) In Cash and Cash Equivalents
   (24,483 ) 47,598
Cash and Cash Equivalents, Beginning of Period
   75,602 66,269


Cash and Cash Equivalents, End of Period
   $ 51,119 $ 113,867


	Six Months Ended November 30,
	2022			2021
Cash Flows (For) From Operating Activities
Net Income (Loss)	$	(36,632	)	$	27,905
Adjustments to reconcile net income to net cash (for) from operating activities:
Depreciation and amortization		32,467			11,511
Deferred income taxes		(1,983	)		(88	)
Share-based compensation		4,499			3,438
Disposal of property and equipment		(456	)		—
Change in operating assets and liabilities, net of business acquisitions:
Accounts receivable		(44,452	)		(1,500	)
Inventories		6,478			(6,929	)
Prepaid expenses and other current assets		(37,833	)		(3,709	)
Accounts payable, accruals and other changes		30,070			10,429
Financing fee amortization		999			—
Interest expense accrual		13,974			—

Net Cash (For) From Operating Activities		(32,869	)		41,057
Cash Flows (For) From Investing Activities
Purchases of property, equipment and other non-current intangible assets		(25,102	)		(5,235	)
Proceeds from the sale of marketable securities		172,763			197,941
Purchases of marketable securities		(12,523	)		(230,586	)
Proceeds from the sale of property and equipment		606			—
Business acquisitions, net of working capital adjustments and cash acquired		38,896			(26,864	)

Net Cash (For) From Investing Activities		174,640			(64,744	)
Cash Flows (For) From Financing Activities
Exercise of stock options and issuance of employee stock purchase plan shares		920			6,619
Financing fees paid		(19,276	)		—
Repayment of debt		(60,000	)		—

Net Cash (For) From Financing Activities		(78,356	)		6,619
Effect of Foreign Exchange Rates on Cash		(7,888	)		(7,415	)

Net Increase (Decrease) In Cash and Cash Equivalents		55,527			(24,483	)
Cash and Cash Equivalents, Beginning of Period		44,473			75,602

Cash and Cash Equivalents, End of Period	$	100,000		$	51,119

See notes to interim consolidated financial statements.

Table of Contents

NEOGEN CORPORATION AND SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. ~~ACCOUNTING POLICIES~~DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

DESCRIPTION OF BUSINESS

Neogen Corporation and subsidiaries develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. Our Food Safety segment consists primarily of diagnostic test kits and complementary products (e.g., culture media) sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant

by-products,

meat speciation, drug residues, pesticide residues and general sanitation concerns. Our diagnostic test kits are generally easier to use and provide greater accuracy and speed than conventional diagnostic methods. The majority of the test kits are disposable,

single-use,

immunoassay and DNA detection products that rely on proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results. Our expanding line of food safety products also includes genomics-based diagnostic technology, and advanced software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.

MERGER WITH THE FOOD SAFETY BUSINESS OF 3M

On September 1, 2022, the Company completed its merger (the “Merger”) with Garden SpinCo, a newly formed

wholly owned subsidiary of 3M created to carve out 3M’s Food Safety Division (“3M FSD”, “FSD”), in a Reverse Morris Trust transaction. The purchase price consideration was

$3.2 billion, net of customary purchase price adjustments and transaction costs, which consisted of 108.3 million shares of Neogen common stock issued on closing. Immediately following the transaction, Garden SpinCo stockholders owned, in the aggregate,

approximately 50.1% of the issued and outstanding shares of Neogen common stock and

pre-merger

Neogen shareholders owned, in the aggregate, approximately 49.9% of the issued and outstanding shares of Neogen common stock.

Neogen was deemed to be the accounting acquiror of the 3M FSD for accounting purposes under U.S. generally accepted accounting principles.

BASIS OF PRESENTATION AND CONSOLIDATION

The accompanying unaudited consolidated financial statements include the accounts of Neogen Corporation (“Neogen” or the “Company”) and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form

10-Q

and Article 10 of Regulation

S-X.

Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of the interim period have been included in the accompanying unaudited consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. The results of operations for the three and six month periods ended November 30, ~~2021~~2022 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, ~~2022.~~2023. For more complete financial information, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on

Form

10-K

for the fiscal year ended May 31, ~~2021.~~2022.

Our functional currency is the U.S. dollar. We translate our

non-U.S.

operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in other comprehensive income (loss). Gains or losses from foreign currency transactions are included in other income (expense) on our consolidated ~~statement~~statements of ~~income.~~

~~Share and per share amounts reflect the June 4, 2021~~

~~2-for-1~~

~~stock split as if it took place at the beginning of the periods presented.~~

~~Recently Adopted Accounting Standards~~

~~Income Tax Simplification~~

~~On June 1, 2021, the Company adopted ASU 740 Update~~

~~2019-12,~~

~~Income Taxes (Topic 740). This guidance provides amendments to simplify the accounting for~~ income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The adoption of this guidance did not have a material impact on our consolidated financial statements.(loss).

~~Recent Accounting Pronouncements Not Yet Adopted~~

~~Reference Rate Reform~~

~~In March 2020, the FASB issued Update~~

~~2020-04,~~

Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This update provides temporary optional expedients to applying the reference rate reform guidance to contracts that reference LIBOR or another reference rate expected to be discontinued. Under this update, contract modifications resulting in a new reference rate may be accounted for as a continuation of the existing contract. This guidance is effective upon issuance of the update and applies to contract modifications made through December 31, 2022. We will adopt this standard when LIBOR is discontinued and our lender begins using the new reference rate. We are evaluating the impact the new standard will have on our consolidated financial statements and related disclosures, but do not anticipate a material impact.

Table of Contents

ACCOUNTING POLICIES

Comprehensive Income (Loss)

Comprehensive income (loss) represents net income and any revenues, expenses, gains and losses that, under U.S. generally accepted

accounting principles, are excluded from net income and recognized directly as a component of equity. Accumulated other

comprehensive income (loss) consists of foreign currency translation adjustments and unrealized gains or losses on our marketable ~~securities.~~securities and derivative instruments.

Fair Value of Financial Instruments

The carrying amounts of the Company’s financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments.

Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows:

Level 1: Observable inputs such as quoted prices in active markets;

Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

~~assumptions.~~

The carrying amounts of certain financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, our revolving credit agreement, and long-term debt, approximate their fair value based on either their short maturity or current terms for similar instruments.

Leases

We lease various manufacturing, laboratory, warehousing and distribution facilities, administrative and sales offices, equipment and vehicles under operating leases. We evaluate our contracts to determine if an arrangement is a lease at inception and classify it as a finance or operating lease. Currently, all our leases are classified as operating leases. ~~Topic 842 requires the~~The Company ~~to recognize~~recognizes a lease liability in the statement of financial position ~~a liability~~ to make lease payments ~~(the lease liability)~~ and a

right-of-use

asset representing its right to use the underlying asset for the lease term.

Right-of-use

assets are recorded in other assets on our consolidated balance sheets. Current and

non-current

lease liabilities are recorded in other accruals within current liabilities and other

non-current

liabilities, respectively, on our consolidated balance sheets. Costs associated with operating leases are recognized on a straight-line basis within operating expenses over the term of the lease. The

right-of-use

assets were ~~$2,171,000~~$

3,707,000 and ~~$2,477,000~~$3,184,000 at November 30, ~~2021~~2022 and May 31, ~~2021,~~2022, respectively. The total current and

non-current

lease liabilities were ~~$2,181,000~~$3,630,000 and ~~$2,492,000~~$3,228,000 at November 30, ~~2021~~2022 and May 31, ~~2021,~~2022, respectively.

Derivatives

We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates. and changes in interest rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, we enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions and have also entered into interest rate swap contracts as a hedge against changes in interest rates. All derivatives are recognized as assets or liabilities and measured at fair value. For derivatives that are determined to be effective hedges, changes in fair value are recognized on other comprehensive income (loss) until the underlying hedged item is recognized in earnings. Derivatives that are not determined to be effective hedges are adjusted to fair value with a corresponding adjustment to earnings. We do not use financial instruments for trading or speculative purposes.

ESTIMATES AND ASSUMPTIONS

The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including, but not limited to, variable consideration related to revenue recognition, allowances for doubtful accounts, the market value of, and demand for, inventories, stock-based compensation, provision for income taxes and related balance sheet accounts, accruals, goodwill and other intangible ~~assets.~~assets and derivatives. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Table of Contents

Accounts Receivable ~~Allowance~~

and Concentrations of Credit Risk

Financial instruments which potentially subject Neogen to concentrations of credit risk consist principally of accounts receivable. Management attempts to minimize credit risk by reviewing customers’ credit ~~history~~histories before extending credit and by monitoring credit exposure on a regular basis. ~~An allowance for doubtful accounts is established based upon factors surrounding the credit risk of specific customers, historical trends and other information.~~ Collateral or other security is generally not required for accounts receivable. We maintain an allowance for customer accounts that reduces receivables to amounts that are expected to be collected. In estimating the allowance for doubtful accounts, management considers relevant information about past events, current conditions and reasonable and supportable forecasts that affect the collectability of financial assets. Once a receivable balance has been determined to be uncollectible, generally after all collection efforts have been exhausted, that amount is charged against the allowance for doubtful accounts. No customer accounted for more than 10% of accounts receivable November 30, 2022 or May 31, 2022, respectively.

Inventory

The reserve for obsolete and slow-moving inventory is reviewed at least quarterly based on an analysis of the inventory, considering the current condition of the asset as well as other known facts and future plans. The reserve required to record inventory at lower of cost or net realizable value is adjusted as conditions change. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations.

Goodwill and Other Intangible Assets

Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts are allocated to other identifiable intangible assets. Other intangible assets include customer relationships, trademarks, licenses, trade names, covenants

not-to-compete

and patents. Customer-based intangibles are amortized on either an accelerated or straight-line basis, reflecting the pattern in which the economic benefits are consumed, while all other amortizable intangibles are amortized on a straight-line basis; intangibles are generally amortized over 5 to 25 years. We review the carrying amounts of goodwill and other

non-amortizable

intangible assets annually, or when indications of impairment exist, to determine if such assets may be impaired. If the carrying amounts of these assets are deemed to be less than fair value based upon a discounted cash flow analysis and comparison to comparable EBITDA multiples of peer companies, such assets are reduced to their estimated fair value and a charge is recorded to operations.

Long-Lived Assets

Management reviews the carrying values of its long-lived assets to be held and used, including definite-lived intangible assets, for

possible impairment whenever events or changes in business conditions warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated separately identifiable undiscounted cash flows over the remaining useful life of the asset indicate that the carrying amount of the asset may not be recoverable. In such an event, fair value is determined using discounted cash flows and, if lower than the carrying value, impairment is recognized through a charge to operations.

Business Combinations

We utilize the acquisition method of accounting for business combinations. This method requires, among other things, that results of operations of acquired companies are included in Neogen’s results of operations beginning on the respective acquisition dates and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Any excess of the fair value of consideration transferred over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized at the estimated fair value on the acquisition date; these are recorded in either other accruals within current liabilities (for expected payments in less than a year) or other

non-current

liabilities (for expected payments in greater than a year), both on our consolidated balance sheets. Subsequent changes to the fair value of contingent consideration liabilities are recognized in other income (expense) in the consolidated statements of income

(loss)

. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other business acquisition costs are expensed when incurred.

Table of Contents

Equity Compensation Plans

Share options awarded to employees, restricted stock units (RSUs) and shares of stock awarded to employees under certain stock purchase plans are recognized as compensation expense based on their fair value at grant date. The fair market value of options granted under the Company stock option plans was estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for inputs such as interest rates, expected dividends, an estimate of award forfeitures, volatility measures and specific employee exercise behavior patterns based on statistical data. Some of the inputs used are not market-observable and have to be estimated or derived from available data. Use of different estimates would produce different option values, which in turn would result in higher or lower compensation expense recognized. For RSUs, we use the intrinsic value method to value the units.

To value equity awards, several recognized valuation models exist; none of these models can be singled out as being the best or most correct. The model applied by us can

accommodate

most of the specific features included in the options granted, which are the reason for their use. If different models were used, the option values could differ despite using the same inputs. Accordingly, using different assumptions coupled with using a different valuation model could have a significant impact on the fair value of employee stock options. Fair value could be either higher or lower than the number provided by the model applied and the inputs used. Further information on our equity compensation plans, including inputs used to determine the fair value of options, is disclosed in Note 7.

Income Taxes

We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are

determined based on differences between the financial reporting and tax bases of assets and liabilities and for tax credit carryforwards and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense represents the change in net deferred income tax assets and liabilities during the year.

New Accounting Pronouncements Not Yet Adopted

Acquired contract assets and liabilities in a business combination

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which amends ASC 805 to require an acquirer to, at the date of acquisition, recognize and measure contract assets and contract liabilities acquired in accordance with ASU 2014-9, Revenue from Contracts with Customers (Topic 606) as if the entity had originated the contracts. The guidance is effective for fiscal years beginning after December 15, 2022. The Company will adopt this guidance in the event of a business combination subsequent to the effective date of the guidance.

Accounting Pronouncements Recently Adopted

Reference Rate Reform

In March 2020, the FASB issued Update

2020-04,

Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This update provides temporary optional expedients to applying the reference rate reform guidance to contracts that reference LIBOR or another reference rate expected to be discontinued. Under this update, contract modifications resulting in a new reference rate may be accounted for as a continuation of the existing contract. We adopted this standard in the second quarter of fiscal 2023, and now use the Secured Overnight Financing Rate (SOFR). Adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

2. CASH AND MARKETABLE SECURITIES

Cash and Cash Equivalents

Cash and cash equivalents consist of bank demand accounts, savings deposits, certificates of deposit and commercial paper with

original maturities of 90 days or less. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has not experienced losses related to these balances and believes it is not exposed to significant credit risk regarding its cash and cash equivalents. Cash and cash equivalents were ~~$51,119,000~~$100,000,000 and ~~$75,602,000~~ $

44,473,000

at November 30, ~~2021~~2022 and May 31, ~~2021,~~2022, respectively. The carrying value of these assets approximates fair value due to the short maturity of these instruments and is classified as Level 1 in the fair value hierarchy.

Marketable Securities

The Company has marketable securities held by banks or broker-dealers at November 30, ~~2021.~~2022. Changes in market value are monitored and recorded on a monthly basis; in the event of a downgrade in credit quality subsequent to purchase, the marketable securities investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable securities portfolio. These securities are classified as available for sale. The primary objective of management’s short-term investment activity is to preserve capital for the purpose of funding current operations, capital expenditures and business acquisitions; short-term investments are not entered into for trading or speculative purposes. These securities

Table of Contents

are recorded at fair value based on recent trades or pricing models and therefore meet the Level 2 criteria. Interest income on these investments is recorded within other income on the income statement. Adjustments in the fair value of these assets are recorded in other comprehensive income.

Marketable Securities as of November 30, ~~2021~~2022 and May 31, ~~2021~~2022 are listed below by classification and remaining maturities.


		November 30,		May 31,
(in thousands)	Maturity	2021		2021		Maturity		November 30, 2022		May 31, 2022
Commercial Paper & Corporate Bonds	0 - 90 days		79,830		106,631		0 - 90 days	$	61,104	$	106,497
	91 - 180 days		88,246		78,727		91 - 180 days		34,200		61,373
	181 days - 1 year		64,526		87,590		181 days - 1 year		57,151		91,706
	1 - 2 years		104,275		26,752		1 - 2 years		23,883		77,002
Certificates of Deposit	0 - 90 days		1,002		3,262
	91 - 180 days		251		1,260
	181 days - 1 year		0		1,263
	1 - 2 years		0		0

Total Marketable Securities		$	338,130	$	305,485			$	176,338	$	336,578

The components of marketable securities, consisting of commercial paper and corporate bonds, at November 30, ~~2021~~2022 are as follows:

Amortized

Unrealized

Unrealized

(in thousands)

Cost

Gains

Losses

Fair Value

Commercial Paper & Corporate Bonds
   337,437    18    (578 )    336,877
Certificates of Deposit
   1,251    2    0—      1,253








Total Marketable Securities
   $ 338,688    $ 20    $ (578 )    $ 338,130


(in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial Paper & Corporate Bonds	$	179,650	$	—	$	(3,312	)	$	176,338

The components of marketable securities, consisting of commercial paper and corporate bonds, at May 31, ~~2021~~2022 are as follows:


	Amortized		Unrealized		Unrealized
(in thousands)	Cost		Gains		Losses			Fair Value		Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial Paper & Corporate Bonds		299,524		209		(33	)		299,700	$	339,540	$	7	$	(2,969	)	$	336,578
Certificates of Deposit		5,755		30		0—			5,785

Total Marketable Securities	$	305,279	$	239	$	(33	)	$	305,485

3. INVENTORIES

Inventories are stated at the lower of cost, determined by the

first-in,

first-out

method, or net realizable value. The components of inventories follow:


	November 30,		May 31,
(in thousands)	2021		2021		November 30, 2022		May 31, 2022
Raw materials	$	53,940	$	47,588	$	68,884	$	58,667
Work-in-process		6,303		6,412		6,013		6,388
Finished and purchased goods		46,843		46,701		61,172		57,258

	$	107,086	$	100,701	$	136,069	$	122,313

Table of Contents

4. REVENUE RECOGNITION

The Company determines the amount of revenue to be recognized through application of the following steps:

Identification of the contract with a customer;

Identification of the performance obligations in the contract;

Determination of the transaction price;

Allocation of the transaction price to the performance obligations in the contract; and

Recognition of revenue when, or as, the Company satisfies the performance obligations.

Essentially all of Neogen’s revenue is generated through contracts with its customers. A performance obligation is a promise in a contract to transfer a product or service to a customer. We generally recognize revenue at a point in time when all of our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control of promised products and services in an amount that reflects the consideration we expect to receive in exchange for those products or services. The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet and the revenue is recognized in the period that all recognition criteria have been met.

Certain agreements with customers include discounts or rebates on the sale of products and services applied retrospectively, such as volume rebates achieved by purchasing a specified purchase threshold of goods and services. We account for these discounts as variable consideration and estimate the likelihood of a customer meeting the threshold in order to determine the transaction price using the most predictive approach. We typically use the most-likely-amount method for incentives that are offered to individual customers, and the expected-value method for programs that are offered to a broad group of customers. Variable consideration reduces the amount of revenue that is recognized. Rebate obligations related to customer incentive programs are recorded in accrued liabilities; the rebate estimates are adjusted at the end of each applicable measurement period based on information currently available.

The performance obligations in Neogen’s contracts are generally satisfied well within one year of contract inception. In such cases, management has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. Management has elected to utilize the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred because the amortization period for the prepaid costs that would otherwise have been deferred and amortized is one year or less. We account for shipping and handling for products as a fulfillment activity when goods are shipped. Shipping and handling costs that are charged to and reimbursed by the customer are recognized as revenues, while the related expenses incurred by Neogen are recorded in sales and marketing expense. Revenue is recognized net of any tax collected from customers; the taxes are subsequently remitted to governmental authorities. Our terms and conditions of sale generally do not provide for returns of product or reperformance of service except in the case of quality or warranty issues. These situations are infrequent; due to immateriality of the amount, warranty claims are recorded in the period incurred.

The Company derives revenue from two primary sources—product revenue and service revenue.

Product revenue consists of shipments of:

Diagnostic test kits, dehydrated culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation;

Consumable products marketed to veterinarians, retailers, livestock producers and animal health product distributors; and

Rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Revenues for our products are recognized and invoiced when the product is shipped to the customer.

Service revenue consists primarily of:

Genomic identification and related interpretive bioinformatic services; and

Other commercial laboratory services.

Revenues for Neogen’s genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer.

Table of Contents

Payment terms for products and services are generally 30 to 60 days.

The Company has no contract assets; contract liabilities represent deposits made by customers before the satisfaction of performance obligation(s) and recognition of revenue. Upon completion of the performance obligation(s) that the Company has with the customer, the liability for the customer deposit is relieved and revenue is recognized. These customer deposits are listed as Deferred Revenue on the consolidated balance sheets.

On September 1, 2022, Neogen closed on a Reverse Morris Trust transaction to combine with 3M’s Food Safety business. Similar to Neogen, 3M’s former Food Safety business sells diagnostic test kits, dehydrated culture media, and related products used by food producers and processors to detect foodborne bacteria, allergens and levels of general sanitation. Revenue for these products are recognized and invoiced when the product is shipped to the customer. These products are currently invoiced and distributed by 3M on behalf of Neogen under a number of transition service contracts.

The following table presents disaggregated revenue by major product and service categories for the three and six month periods ended November 30, ~~2021~~2022 and ~~2020:~~

2021:

Three Months ended
November 30,

Six Months ended
November 30,

(in thousands)

2021

2020

2021

2020

Food Safety

Natural Toxins, Allergens & Drug Residues
   $ 21,028    $ 20,001    $ 41,432    $ 39,016
Bacterial & General Sanitation
   12,252    11,235    23,421    21,166
Culture Media & Other
   19,935    14,215    37,981    26,387
Rodenticides, Insecticides & Disinfectants
   8,232    7,059    15,882    15,888
Genomics Services
   5,685    5,024    11,138    9,262








   $ 67,132    $ 57,534    $ 129,854    $ 111,719
Animal Safety

Life Sciences
   $ 1,309    $ 1,398    $ 2,672    $ 2,723
Veterinary Instruments & Disposables
   15,572    11,974    30,909    22,349
Animal Care & Other
   10,849    9,371    20,068    17,029
Rodenticides, Insecticides & Disinfectants
   18,269    18,471    40,418    38,385
Genomics Services
   17,386    16,252    34,901    32,120








   $ 63,385    $ 57,466    $ 128,968    $ 112,606








Total Revenues
   $ 130,517    $ 115,000    $ 258,822    $ 224,325


	Three Months ended November 30,				Six Months ended November 30,
(in thousands)	2022		2021		2022		2021
Food Safety
Natural Toxins, Allergens & Drug Residues	$	22,251	$	21,028	$	42,038	$	41,432
Bacterial & General Sanitation		41,121		12,252		51,849		23,421
Culture Media & Other		82,084		19,935		101,338		37,981
Rodent Control, Insect Control & Disinfectants		10,377		8,232		19,952		15,882
Genomics Services		5,510		5,685		10,809		11,138

		161,343		67,132		225,986		129,854
Animal Safety
Life Sciences		1,427		1,309		3,016		2,672
Veterinary Instruments & Disposables		16,433		15,572		31,106		30,909
Animal Care & Other		10,569		10,849		21,095		20,068
Rodent Control, Insect Control & Disinfectants		20,665		18,269		42,879		40,418
Genomics Services		19,596		17,386		38,300		34,901

		68,690		63,385		136,396		128,968

Total Revenues	$	230,033	$	130,517	$	362,382	$	258,822

5. NET INCOME (LOSS) PER SHARE

The calculation of net income (loss) per share

follows:

Three Months Ended

Six Months Ended


November 30,

November 30,

(in thousands, except per share amounts)

2021

2020

2021

2020

Numerator for basic and diluted net income per share:

Net income attributable to Neogen
   $ 10,828    $ 15,885    $ 27,905    $ 31,745
Denominator for basic net income per share:

Weighted average shares
   107,641    106,258    107,565    106,044
Effect of dilutive stock options and RSUs
   481    550    534    556








Denominator for diluted net income per share
   108,122    106,808    108,099    106,600
Net income attributable to Neogen per share:

Basic
   $ 0.10    $ 0.15    $ 0.26    $ 0.30








Diluted
   $ 0.10    $ 0.15    $ 0.26    $ 0.30


	Three Months Ended November 30,					Six Months Ended November 30,
(in thousands, except per share amounts)	2022			2021		2022			2021
Numerator for basic and diluted net income (loss) per share:
Net income (loss) attributable to Neogen	$	(41,841	)	$	10,828	$	(36,632	)	$	27,905
Denominator for basic net income (loss) per share:
Weighted average shares		216,134			107,641		161,690			107,565
Effect of dilutive stock options and RSUs		—			481		—			534

Denominator for diluted net income (loss) per share	$	216,134		$	108,122	$	161,690		$	108,099
Net income (loss) per share:
Basic	$	(0.19	)	$	0.10	$	(0.23	)	$	0.26
Diluted	$	(0.19	)	$	0.10	$	(0.23	)	$	0.26

Note:

Due to the net loss for the Three and Six month periods end November 30, 2022, the dilutive stock options and RSUs are anti-dilutive for those periods.

133

Table of Contents

6. SEGMENT INFORMATION AND GEOGRAPHIC DATA

We ~~have2~~have two reportable segments:

Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits, culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. All new products from the merger of the 3M FSD, effective September 1, 2022, are reported through the Food Safety segment. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors; this segment also provides genomic identification and related interpretive bioinformatic services. Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Our international operations in the United Kingdom, Mexico, Brazil, China and India originally focused on the Company’s food safety products, and each of these units reports through the Food Safety segment. In recent years, these operations have expanded to offer our complete line of products and services, including those usually associated with the Animal Safety segment such as cleaners, disinfectants, rodenticides, insecticides, veterinary instruments and genomics services. These additional products and services are managed and directed by existing management and are reported through the Food Safety segment.

Neogen’s operation in Australia originally focused on providing genomics services and sales of animal safety products and reports through the Animal Safety segment. With the acquisition of Cell BioSciences in February 2020, this operation ~~has~~ expanded to offer our complete line of products and services, including those usually associated with the Food Safety segment. These additional products are managed and directed by existing management at Neogen Australasia and report through the Animal Safety segment.

The accounting policies of each of the segments are the same as those described in Note 1.

Segment information follows:


						Corporate and
		Food		Animal		Eliminations
(in thousands)		Safety		Safety		(1)			Total		Food Safety		Animal Safety		Corporate and Eliminations (1)			Total
As of and for the three months ended November 30, 2022
Product revenues to external customers											$	154,223	$	49,094	$	—		$	203,317
Service revenues to external customers												7,120		19,596		—			26,716

Total revenues to external customers											$	161,343	$	68,690	$	—		$	230,033

Operating income (loss)											$	21,446	$	12,806	$	(41,908	)	$	(7,656	)
Total assets											$	3,955,488	$	329,177	$	278,577		$	4,563,242

As of and for the three months ended November 30, 2021	As of and for the three months ended November 30, 2021
Product revenues to external customers		$	60,112	$	45,999	$	—		$	106,111	$	60,112	$	45,999	$	—		$	106,111
Service revenues to external customers			7,020		17,386		—			24,406		7,020		17,386		—			24,406

Total revenues to external customers			67,132		63,385		—			130,517	$	67,132	$	63,385	$	—		$	130,517

Operating income (loss)			10,894		12,701		(11,126	)		12,469	$	10,894	$	12,701	$	(11,126	)	$	12,469
Total assets			298,437		278,994		390,503			967,934	$	298,437	$	278,994	$	390,503		$	967,934
As of and for the three months ended November 30, 2020
Product revenues to external customers		$	51,323	$	41,214	$	—		$	92,537
Service revenues to external customers			6,211		16,252		—			22,463

Total revenues to external customers			57,534		57,466		—			115,000
Operating income (loss)			8,960		12,246		(1,961	)		19,245
Total assets			226,735		228,126		390,765			845,626

(1)	Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.

Table of Contents


					Corporate and
	Food		Animal		Eliminations
(in thousands)	Safety		Safety		(1)			Total		Food Safety		Animal Safety		Corporate and Eliminations (1)			Total
As of and for the six months ended November 30, 2022
Product revenues to external customers										$	212,013	$	98,096	$	—		$	310,109
Service revenues to external customers											13,973		38,300		—			52,273

Total revenues to external customers										$	225,986	$	136,396	$	—		$	362,382

Operating income (loss)										$	30,042	$	24,687	$	(56,323	)	$	(1,594	)

As of and for the six months ended November 30, 2021
Product revenues to external customers	$	116,057	$	94,067	$	—		$	210,124	$	116,057	$	94,067	$	—		$	210,124
Service revenues to external customers		13,797		34,901		—			48,698		13,797		34,901		—			48,698

Total revenues to external customers		129,854		128,968		—			258,822	$	129,854	$	128,968	$	—		$	258,822

Operating income (loss)		21,026		25,463		(12,275	)		34,214	$	21,026	$	25,463	$	(12,275	)	$	34,214
As of and for the six months ended November 30, 2020
Product revenues to external customers	$	99,986	$	80,486	$	—		$	180,472
Service revenues to external customers		11,733		32,120		—			43,853

Total revenues to external customers		111,719		112,606		—			224,325
Operating income (loss)		16,923		24,411		(3,194	)		38,140

(1)	Includes elimination of intersegment transactions.

The following table presents the Company’s revenue disaggregated by geographic location:

Three months ended

Six months ended


November 30,

November 30,

(in thousands)

2021

2020

2021

2020

Domestic
   $ 76,378    $ 69,832    $ 154,156    $ 137,156
International
   54,139    45,168    104,666    87,169








Total revenue
   130,517    115,000    258,822    224,325


	Three months ended November 30,				Six months ended November 30,
(in thousands)	2022		2021		2022		2021
Domestic	$	114,413	$	76,378	$	195,055	$	154,156
International		115,620		54,139		167,327		104,666

Total revenue	$	230,033	$	130,517		362,382		258,822

7. EQUITY COMPENSATION PLANS

Incentive and

non-qualified

options to purchase shares of common stock have been granted to directors, officers and employees of Neogen under the terms of the Company’s stock option plans. These options are granted at an exercise price of not less than the fair market value of the stock on the date of grant. Options vest ratably over three and five year periods and the contractual terms are generally five, seven or ten years. A summary of stock option activity during the six months ended November 30, ~~2021~~2022 follows:

Weighted-


Average

(Options in thousands)

Shares

Exercise Price

Options outstanding June 1, 2021
   2,957    $ 30.38
Granted
   392    40.93
Exercised
   (262 )    22.42
Forfeited
   (21 )    31.11



Options outstanding November 30, 2021
   3,066    $ 32.40


(options in thousands)	Shares			Weighted- Average Exercise Price
Options outstanding June 1, 2022		3,244		$	32.13
Granted		1,687			14.63
Exercised		(4	)		10.75
Forfeited/Expired		(592	)		29.75

Options outstanding November 30, 2022		4,335		$	25.66

During the three and six month periods ended November 30, ~~2021~~2022 and ~~2020,~~2021, the Company recorded $2,632,000 and $1,748,000, and ~~$1,511,000~~$4,499,000 and $3,438,000, ~~and $3,192,000,~~

respectively, of ~~compensation~~ expense related to its share-based ~~awards.~~awards, recorded in general and administrative expense in the consolidated income statement.

Table of Contents

The weighted-average fair value per share of stock options granted during the first six months of fiscal years ~~2022~~2023 and ~~2021,~~2022, estimated on the date of grant using the Black-Scholes option pricing model, was ~~$9.54~~ $

4.59

and ~~$7.71, respectively.~~ $

9.54

The fair value of stock options granted was estimated using the following weighted-average assumptions.


	FY 2022			FY 2021			FY 2023			FY 2022
Risk-free interest rate		0.4	%		0.2	%		3.3	%		0.4	%
Expected dividend yield		0.0	%		0.0	%		0.0	%		0.0	%
Expected stock price volatility		32.8	%		31.3	%		34.0	%		32.8	%
Expected option life		3.12 years			3.25 years			4.61 years			3.12 years

The company grants restricted stock units (RSUs) to directors, officers and employees under the terms of the 2018 Omnibus Incentive Plan, which vest ratably over three and five year periods. The current units are expensed straight-line over the remaining weighted-average period of ~~4.32~~3.2 years. On November 30, ~~2021~~2022 there was ~~$6,501,000~~$12,820,000 in unamortized compensation cost related to

non-vested

RSUs. A summary of RSU activity during the six months ended November 30, 2022 follows:


(RSUs in thousands)	Shares			Weighted- Average Fair Value
RSUs outstanding June 1, 2022		257		$	36.14
Granted		584			13.72
Released		(47	)		37.62
Forfeited/Cancelled		(5	)		37.63

RSUs outstanding November 30, 2022		789		$	19.46

Under the terms of an agreement entered into with 3M as part of the combination of the FSD, the Company issued stock options and RSUs to conveying 3M employees to replace their existing unvested 3M awards under an exchange ratio based on the closing prices of Neogen and 3M common stock on August 31, 2022, the day before the transaction.

Weighted-


Average

(Options in thousands)

Shares

Fair Value

RSUs outstanding June 1, 2021
   121    $ 34.21
Granted
   120    40.92
Released
   (25 )    34.24
Forfeited
   (3 )    34.49



RSUs outstanding November 30, 2021
   213    $ 37.97

These substitute options and RSUs retained their original vesting and expiration terms

(originally three year vesting and ten year lives). There were a total of 131,746 substitute options and 29,770 substitute RSUs issued during the second quarter to the conveying

3M employees as part of the employee matters agreement; the Company recognized

$184,000

in compensation expense (included in the overall compensation expense of

2,632,000

) during the quarter for these awards.

The Company offers eligible employees the option to purchase common stock at a 5% discount to the lower of the market value of the stock at the beginning or end of each participation period under the terms of ~~either the 2011 or~~ the 2021 Employee Stock Purchase Plan; the discount is recorded in general and administrative expense. Total individual purchases in any year are limited to 10% of compensation.

8. BUSINESS COMBINATIONS

The ~~Consolidated Statements~~consolidated statements of ~~Income~~income (loss) reflect the results of operations for business acquisitions since the respective dates of purchase. A

lAll are accounted for using the acquisition method. Goodwill recognized in the acquisitions discussed below relates primarily to enhancing the Company’s strategic platform for the expansion of available product offerings.

On ~~July 31, 2020, the Company acquired the U.S. (including territories) rights to Elanco’s StandGuard~~

~~Pour-on~~

for horn fly and lice control in beef cattle, and related assets. This product line fits in well with Neogen’s existing agricultural insecticide portfolio and organizational capabilities. Consideration for the purchase was $2,351,000 in cash, all paid at closing. The final purchase price allocation, based upon the fair value of these assets determined using the income approach, included inventory of $51,000 and intangible assets of $2,300,000 (with an estimated life of 15 years). This product line is manufactured at Neogen’s operation in Iowa; the sales are reported within the Animal Safety segment.

~~On December 30, 2020,~~September 17, 2021, the Company acquired all of the stock of Megazyme, Ltd, an Ireland-based company, and its wholly-owned subsidiaries, U.S.-based Megazyme, Inc. and Ireland-based Megazyme IP. Megazyme is a manufacturer and supplier of diagnostic assay kits and enzymes to measure dietary fiber, complex carbohydrates and enzymes in food and beverages as well as animal feeds. This acquisition

~~has~~

~~allow~~

Neogen to expand its commercial relationships across food, feed and beverage companies, and provide additional food quality diagnostic products to commercial labs and food science research institutions. Consideration for the purchase was net cash of $39.8 million paid at closing, $8.6 million of cash placed in escrow payable to the former owner in two installments in two and four years, $4.9 million of stock issued at closing, and up to $2.5 million of contingent consideration, payable in two installments over

~~one~~

~~year, based upon an excess net sales formula. The~~

~~final~~

purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $1,376,000, inventory of $5,595,000, net property, plant and equipment of $12,599,000, prepayments of $69,000, accounts payable of $4,000, other current liabilities of $1,815,000, contingent consideration accrual of $2,458,000,

~~non-current~~

~~liabilities of $319,000,~~

~~non-current~~

~~deferred tax liabilities of $3,306,000, intangible assets of $22,945,000 (with an estimated life of~~

~~15-20~~

~~years) and the remainder to goodwill~~

~~(non-deductible~~

for tax purposes). These values are Level 3 fair value measurements. In February 2021, the former owner was paid $1,229,000 for the first installment of contingent consideration, based upon the achievement of sales targets. The Irish companies continue to operate from their current locations in Bray, Ireland, reporting within the Food Safety segment and are managed through Neogen’s Scotland operation. The U.S. company’s business is managed by our Lansing-based Food Safety team.

~~On September 17, 2021, the Company acquired the stock of~~ CAPInnoVet, Inc., a companion

animal health business that provides pet medications to the veterinary market. This acquisition provides entry into the retail parasiticide market and enhances the Company’s presence in companion animal markets. Consideration for the purchase was net cash of $17.9 million paid at closing, including $150,000 of cash placed in escrow payable to the former owners in ~~twelve~~12 months. There is also the potential for

performance

milestone payments to the former owners of up to $6.5 million

and

the Company could incur up to $14.5 million in

future ~~roya~~

~~lty payment~~

.royalty payments. The ~~preliminary~~final purchase allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $308,000, inventory of ~~$408,000,~~$531,000, prepayments of $296,000, accounts payable of $120,000, other current liabilities of ~~$132,000,~~$84,000,

non-current

liabilities of ~~$13.9~~$6.5 million (contingent consideration accrual calculated using a Monte Carlo simulation utilizing inputs such as probability and timing of milestone achievements, revenue forecasts and volatility, and estimated discount rates relating to established future cash flows of the business), intangible assets of ~~$21.0~~$19.2 million (with an estimated life of

15-20

years) and the remainder to goodwill

~~(non-deductible~~

(deductible for tax purposes). These values are Level 3 fair value measurements. The $150,000 placed in escrow was paid to the former owners on September 21, 2022. The business

operated from our location in Lexington, KY, reporting within the Animal Safety segment.

Table of Contents

On November 30, 2021, the Company acquired all of the stock of Delf ~~(UK)~~(U.K.) Ltd., a United Kingdom-based manufacturer and supplier of animal hygiene and industrial cleaning products, and

Abbott

Analytical Ltd.,

a related service provider. This acquisition will expand the Company’s line of dairy hygiene products and will enhance our cleaner and disinfectant product portfolio. Consideration for the purchase was net cash of ~~$8.8~~$9.5 million paid at closing, including $722,000 of cash placed in escrow payable to the former owner in one year. The ~~preliminary~~final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of ~~806,000,~~$1,059,000, inventory of ~~$659,000,~~$972,000, net property, plant and equipment of ~~$160,000,~~$152,000, prepayments of ~~$43,000,~~$31,000, accounts payable of ~~$543,000,~~$497,000, other current liabilities of ~~$489,000,~~$378,000,

non-current

deferred tax liabilities of ~~$533,000,~~$780,000, intangible assets of ~~$2.6~~$3.1 million (with an estimated life of

10-15

years) and the remainder to goodwill

(non-deductible

for tax purposes). These values are Level 3 fair value measurements. The companies continue to operate from their current location in Liverpool, England, reporting within the Food Safety segment and are managed through Neogen’s Scotland operation.

~~Subsequent to the end of the quarter, on~~On December 9, 2021, the Company acquired all of the stock of Genetic Veterinary ~~Services,~~Sciences, Inc., a companion animal genetic testing business providing genetic information for dogs, cats and birds to animal owners, breeders and veterinarians. This acquisition will further expand the Company’s presence in the companion animal market.

Consideration for the purchase was ~~$11.8~~$11.4 million in net cash. ~~Due to the timing of the transaction, the preliminary~~The final purchase price allocation, ~~was not complete at~~based upon the ~~time~~fair value of ~~filing.~~these assets and liabilities determined using the income approach, included accounts receivable of $38,000, net inventory of $292,000, net property, plant and equipment of $399,000, prepayments of $54,000, accounts payable of $325,000, unearned revenue of $1.9 million, other current liabilities of $321,000, intangible assets of $5.5 million (with an estimated life of

5-15

years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. The business ~~will be~~is operated from its current location in Spokane, Washington, reporting within the Animal Safety segment.

~~Subsequent~~

~~to the end~~On July 1, 2022, Neogen acquired all of the ~~quarter, on December 13, 2021, the Company entered into an agreement to combine with 3M’s~~stock of

Thai-Neo

Biotech Co., Ltd., a longstanding distributor of Neogen’s food safety products to Thailand and Southeast Asia. This acquisition gives Neogen a direct sales presence in Thailand. Consideration for the purchase was $1,581,000 in net cash, with $1,310,000 paid at closing, $37,000 paid on November 29, 2022 as a working capital adjustment and $234,000 payable on October 1, 2023. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $177,000, inventory of $232,000, prepaids of $3,000, net property, plant and equipment of $16,000, other

non-current

assets of $6,000, accounts payable of $98,000, other payables of $6,000,

non-current

tax liabilities of $124,000, intangible assets of $620,000 (with an estimated life of 10 years) and the remainder to goodwill

(non-deductible

for tax purposes). The business continues to operate in ~~a Reverse Morris Trust transaction. Please refer to Forms~~

~~8-K~~

~~and Forms 425 filed with~~Bangkok, Thailand, reporting within the ~~Securities and Exchange Commission for more information.~~Food Safety segment.

For each completed acquisition listed above, the revenues and net income were not considered material and were therefore not disclosed.

3M Food Safety transaction

On September 1, 2022, Neogen, 3M Company (“3M”), and Garden SpinCo Corporation (“Garden SpinCo”), a newly formed, wholly owned subsidiary of 3M created to carve out 3M’s Food Safety Division (“3M FSD”, “FSD”), closed on the transaction combining 3M’s FSD with Neogen in a Reverse Morris Trust transaction and Garden SpinCo became a

wholly owned

subsidiary of Neogen (“FSD transaction”). Following the FSD transaction,

pre-merger

Garden SpinCo stockholders own, in the aggregate, approxim

ately

50.1% of the issued and outstanding shares of Neogen common stock and

pre-merger

Neogen shareholders own, in the aggregate, approximately 49.9% of the issued and outstanding shares of Neogen common stock. This transaction is a business combination and will be accounted for using the acquisition method.

The acquired business is a leading provider of food safety testing solutions. It offers a broad range of food safety testing products that support multiple industries within food and beverage, helping producers to prevent and protect consumers from foodborne illnesses. The business has a broad global presence with products used in more than 60 countries and a diversified revenue base of more than 100,000

end-user

customers. The combination of Neogen and the 3M FSD creates a leading innovator with an enhanced geographic footprint, innovative product offerings, digitization capabilities, and financial flexibility to capitalize on robust growth trends in sustainability, food safety, and supply chain integrity. The acquired Food Safety business continues to primarily operate in facilities in Minnesota and the United Kingdom, and is being managed overall in Michigan, reporting within the Food Safety segment.

The purchase price consideration for the 3M FSD was

$3.2 billion, net of customary purchase price adjustments and transaction costs, which consisted of 108,269,946 shares of Neogen common stock issued on closing with a fair value of $2.3 billion and cash consideration of $1

billion, funded by the additional financing secured by the Company.

See Note 10 – Long Term

Debt for further detail on the debt incurred.

Table of Contents

As of November 30, 2022, the Company has recorded a preliminary allocation of the purchase consideration to assets acquired and liabilities assumed based on initial fair value estimates and is subject to continuing management analysis, with assistance from third party valuation advisors. The excess of the purchase price over the fair value of the net tangible assets and identifiable intangible assets

of $

1.96

billion was recorded as goodwill, of which $1.90 billion is not deductible for tax purposes. Goodwill includes value associated with profits earned from market and expansion capabilities, expected synergies from integration and streamlining operational activities, the expertise and reputation of the assembled workforce and other intangible assets that do not qualify for separate recognition. These values are Level 3 fair value measurements. The preliminary fair values of net tangible assets and intangible assets acquired were based on preliminary valuations, and our estimates and assumptions are subject to change within the measurement period (up to one year from the acquisition date). The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.

The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the date of acquisition:


(in thousands)
Cash and cash equivalents	$	319
Inventories		21,402
Other current assets		14,855
Property, plant and equipment		20,010
Intangible assets		1,560,000
Right of use asset		882
Lease liability		(885	)
Deferred tax liabilities		(353,760	)
Other liabil i ties		(3,584	)

Total identifiable assets and liabilities acquired		1,259,239
Goodwill		1,963,171

Total purchase consideration	$	3,222,410

The following table summarizes the intangible assets acquired and the useful life of these assets.


(in thousands)	Fair Value		Useful Life in Years
Trade Names and Trademarks	$	120,000		25
Developed Technology		280,000		15
Customer Relationships		1,160,000		20

Total intangible assets acquired	$	1,560,000

For the three and six months ended November 30, 2022, transaction costs of $39.1 million and $52.9 million, respectively, were expensed; in the prior year second quarter, acquisition related costs of $9.3 million were expensed. These costs are included in general and administrative expenses in the Company’s consolidated statements of income

(loss)

The operating results of the 3M FSD have been included in the Company’s consolidated statements of income

(loss)

since the acquisition date. In the second quarter of fiscal 2023, the 3M FSD’s total revenue

was

$92.7 million and operating loss was approximately $29.7 million. The operating loss includes $39.1 million of transaction costs, $20.3 million of amortization expense for acquired intangible assets and $3.9 million of cost of goods sold related to the step up to fair value on acquired inventory.

The following table presents pro forma information as if the merger with the 3M FSD business had occurred on June 1, 2021 and had been combined with the results reported in our consolidated statements of income

(loss)

for all periods presented:


	Three Months Ended						Six Months Ended
	November 30,						November 30,
in thousands, unaudited	2022			2021			2022			2021
Net sales	$	230,033		$	225,700		$	457,300		$	448,200
Operating Income (loss)	$	(7,700	)	$	(1,600	)	$	(21,100	)	$	6,100

The unaudited pro forma information is presented for informational purposes only and is not indicative of the results that would have been achieved if the merger had taken place at such time. The unaudited pro forma information presented above includes adjustments primarily for amortization charges for acquired intangible assets and certain acquisition-related expenses for legal and professional fees.

In connection with the acquisition of the 3M FSD, the Company and 3M entered into several transition service agreements, including manufacturing, distribution and certain back-office support, that have been accounted for separately from the acquisition of assets and assumption of liabilities in the business combination. 3M periodically remits amounts charged to customers on our behalf and charges us for the associated cost of goods sold and transitions service fees. As of November 30, 2022, a net receivable from 3M of

$36.5

million was included in Prepaid expenses and other current assets in the Company’s consolidated balance sheets.

Table of Contents

9. GOODWILL AND INTANGIBLE ASSETS

The following table summarizes goodwill by reportable segment:


(in thousands)	Food Safety		Animal Safety			Total
May 31, 2022	$	67,558	$	75,146		$	142,704
Acquisitions (1)		1,957,810		6,115		$	1,963,925
Foreign currency translation and other		16,058		(290	)	$	15,768

November 30, 2022	$	2,041,426	$	80,971		$	2,122,397

(1)	Animal Safety acquisitions represents portion of 3M Food Safety transaction recorded at Neogen Australasia.

At November 30, 2022, non-amortizable assets included licenses of $569,000, trademarks of $13,423,000 and other intangibles of $1,224,000. At May 31, 2022, non-amortizable intangible assets included licenses of $569,000, trademarks of $13,604,000 and other intangibles of $1,224,000.

Amortizable intangible assets consisted of the following and are included in customer-based intangibles and other non-current assets within the consolidated balance sheets:


(in thousands)	Gross Carrying Amount		Less Accumulated Amortization		Net Carrying Amount

Licenses	$	16,979	$	6,394		10,585
Covenants not to compete		371		234		137
Patents		8,029		4,565		3,464
Customer relationships		1,234,202		49,735		1,184,467	��
Trade names and trademarks		121,135		1,417		119,718
Developed technology		296,897		11,000		285,897
Other product and service-related intangibles		26,947		4,701		22,245

November 30, 2022	$	1,704,560	$	78,046	$	1,626,514


Licenses	$	17,109	$	5,682	$	11,427
Covenants not to compete		846		671		175
Patents		8,347		4,583		3,764
Customer relationships		75,000		33,662		41,338
Trade names and trademarks		1,180		167		1,013
Developed technology		17,741		6,124		11,617
Other product and service-related intangibles		27,299		4,527		22,772

May 31, 2022	$	147,522	$	55,416	$	92,106

Amortization expense relating to

finite-lived intangible assets was $22.7 million and $2.4 million for the three months ended November 30, 2022 and 2021, respectively, and $25.1 million and $4.6 million for the six months ended November 30, 2022 and 2021, respectively.

The estimated amortization expense for each of the five succeeding fiscal years is as follows: $45.6 million remaining in 2023, $90.8 million in 2024, $90.3 million in 2025, $90.2 million in 2026 and $89.7 million in 2027 and $1.22 billion thereafter.

The amortizable intangible assets useful lives are 2 to 20 years for licenses, 3 to 10 years for covenants not to compete, 5 to 25 years for patents, 9 to 20 years for customer relationships, 10 to 25 years for trade names and trademarks, 10 to 20 years for developed technology and 5 to 15 years for other product and service-related intangibles. All definite-lived intangibles are amortized on a straight-line basis with the exception of definite-lived customer-based intangibles and product and service-related intangibles, which are amortized on either a straight-line or an accelerated basis.

The weighted average remaining amortization period for intangibles was 18 years at November 30, 2022 and eight years at May 31, 2022.

Table of Contents

. LONG TERM DEBT

~~We have~~The Company’s long-term debt consists of the following:


(in thousands)	As of November 30, 2022			As of May 31, 2022
Term Loan	$	590,000		$	—
Senior Notes		350,000			—

Total long-term debt	$	940,000		$	—
Less: Unamortized debt issuance costs		(16,038	)		—

Total non-current debt, net	$	923,962		$	—

The Company had a financing agreement with a bank providing for a ~~$15,000,000~~$15.0 million unsecured revolving line of credit, which ~~expires~~originally expired on November 30, ~~2023.~~2023, but was replaced by the five-year senior secured revolving facility as part of the Credit Facilities described below. There were 0no advances against the line of credit during fiscal ~~2021~~2022 and there ~~have been none thus far~~were no advances in fiscal ~~2022; there~~2023 before the line of credit was ~~0 balance outstanding at November 30, 2021.~~extinguished. Interest on any borrowings isunder that agreement was at LIBOR plus 100 basis ~~points (rate under the terms of the agreement was 1.09% at November 30, 2021).~~points. Financial covenants ~~include~~included maintaining specified levels of tangible net worth, debt service coverage, and funded debt to EBITDA, each of which the Company was in compliance with during the period the line of credit was available.

In connection with the acquisition of 3M’s Food Safety business as described more fully in Note 8, Neogen incurred financing through Garden SpinCo as follows:

Credit Facilities

On June 30, 2022, Garden SpinCo entered into a credit agreement consisting of a five-year senior secured term loan facility (“term loan facility”) in the amount of $650 million and a five-year senior secured revolving facility (“revolving facility”) in the amount of $150 million (collectively, the “Credit Facilities”) to fund the 3M Food Safety transaction. The term loan facility was drawn on August 31, 2022, to fund the closing of the 3M Food Safety transaction on September 1, 2022 while the revolving facility remained undrawn and continues to be undrawn as of November 30, 2022.

The Credit Facilities bear interest based on the term SOFR plus an applicable margin between a range of 150 to 225 basis points determined for each interest period and paid monthly. For the three and six months ended November 30, 2022, the interest rates ranged from 4.80% to 6.08%

per annum. The term loan facility matures

on June 30, 2027 and the revolving facility matures at the earlier of June 30, 2027 and the termination of the revolving commitments.

In addition, the term loan facility contains an optional prepayment feature at the discretion of the Company. The Company determined that the prepayment feature did not meet the definition of an embedded derivative and does not require bifurcation from the host liability and, accordingly, has accounted for the entire instrument at amortized cost. In accordance with the prepayment feature, the Company paid $60 million of the term loan facility’s principal in September 2022 prior to the first scheduled quarterly repayment.

The Company can, at its sole discretion, draw any amount under the revolving facility, with the amount to be repaid on the termination date of the revolving commitments. Debt issuance costs of $2.4 million

were incurred related to the revolving facility. These costs are being amortized as interest expense in the consolidated statements of income (loss) over the contractual life of the revolving facility using the straight line method. Amortization of the deferred debt issuance costs for the revolving facility

was $122,000 for

the three and six month periods ended November 30, 2022. Debt issuance costs of $489,000 were recorded in Prepaid expenses and other current assets and $1.8 million were recorded in Other non-current assets on the consolidated balance sheet at November 30, ~~2021.~~2022. The Company must pay an annual commitment fee ranging

from

0.20

% and

0.35

% on the unused portion of the Revolving Credit Facility, paid quarterly. As of November 30, 2022, the commitment fee was

0.35

% and $

225,000

was recorded as interest expense in the

consolidated statements of income (loss) for the

three and six months ended November 30, 2022.

Total accrued interest on the term loan was $

3.0

million as of November 30, 2022 based on the term SOFR interest rate of

6.08

% and included in current liabilities on the consolidated balance sheets. The Company incurred $10.2

million in total debt issuance costs which is recorded as an offset to the term loan facility and amortized over the contractual life of the loan to interest expense using the straight line method. The amortization of deferred debt issuance costs

of $

529,000

and interest expense of $

8.5

million was

included in the consolidated statements of income (loss) for the

three and six months ended November 30, 2022.

Financial covenants include maintaining specified levels of funded debt to EBITDA, and debt service coverage. At November 30, 2022, the Company was in compliance with its covenants.

~~10.~~20

Table of Contents

Senior Notes

On July 20, 2022, Garden SpinCo closed on an offering of $350 million aggregate principal amount of 8.625% senior notes due 2030

(the “Notes”) in a private placement at par. The Notes were initially issued by Garden SpinCo to 3M and were transferred and delivered by 3M to the selling securityholder in the offering, in satisfaction of certain of 3M’s existing debt. Upon closing of the 3M Food Safety transaction on September 1, 2022, the Notes became guaranteed on a senior unsecured basis by the Company and certain wholly-owned domestic subsidiaries of the Company.

The Company determined that the redemption features of the Notes did not meet the definition of a derivative and thus does not require bifurcation from the host liability and accordingly has accounted for the entire instrument at amortized cost.

Total accrued interest on the Notes was $11.0 million as of November 30, 2022 based on the stated interest rate of 8.625% and included in current liabilities on the consolidated balance sheets. The Company incurred total debt issuance costs of $6.7 million which is recorded as an offset to the Notes and amortized over the contractual life of the Notes to interest expense using the

straight line

method. For the three and six months ended November 30, 2022, the Company recorded $11.0 million of interest expense in the

consolidated statements of income (loss), of

which $348,000 related to the amortization of deferred debt issuance costs.

The expected maturities associated with the Company’s outstanding debt as of November 30, 2022, were as follows:


(in thousands)	Amount
Fiscal Year
Remainder of 2023	$	—
2024		—
2025		—
2026		29,375
2027		44,688
Thereafter		865,937

Total	$	940,000

. INCOME TAXES

Income tax expense in the second quarter of fiscal 2023 was $7.8 million, compared to $2.1 million in the same period of the prior year; for the year to date, income tax expense was $9.2 million, compared to $6.8 million in fiscal 2022. Income tax expense in the second quarter of fiscal 2023 includes approximately $6.7 million of expense related to

non-deductible

transaction costs associated with the 3M Food Safety transaction and $625,000

of expense due to an increase in our state rate for deferred tax liabilities. In each comparative period, there was minimal benefit from the exercise of stock options.

The total amounts of unrecognized tax benefits that, if recognized, would affect the effective tax rate as of November 30, 2022 and May 31, 2022 are $1.4 million and $808,000

, respectively. The increase in unrecognized tax benefits is primarily associated with the acquired 3M FSD, including positions for transfer pricing and research and development credits.

Table of Contents

. COMMITMENTS AND CONTINGENCIES

The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. The Company currently utilizes a pump and treat remediation strategy, which includes semi-annual monitoring and reporting, consulting, and maintenance of monitoring wells. We expense these annual costs of remediation, which have ranged from $38,000 to $131,000 per year over the past five years. The Company’s estimated remaining liability for these costs was $916,000 at both November 30, ~~2021~~2022 and May 31, ~~2021,~~2022, measured on an undiscounted basis over an estimated period of 15 years. In fiscal 2019, the Company performed an updated Corrective Measures Study on the site, per a request from the Wisconsin Department of Natural Resources (WDNR) and is currently in discussion with the WDNR regarding potential alternative remediation strategies going forward. The Company believes that the current pump and treat strategy is appropriate for the site. However, the Company has ~~agreed to~~undertaken a pilot study in which chemical reagents are injected into the ground in an attempt to reduce

on-site

~~contamination and is currently working with its consultant to design the system.~~contamination. At this time, the outcome of the pilot study is unknown, but a change in the current remediation strategy, depending on the alternative selected, could result in an increase in future costs and ultimately, an increase in the currently recorded liability, with an offsetting charge to operations in the period recorded. The Company has recorded ~~$300,000~~$100,000 as a current liability at November 30, 2022, and the remaining ~~$616,000~~$816,000 is recorded in other

non-current

liabilities in the consolidated balance sheets.

On March 6, 2020, the Company received an administrative subpoena from the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC) regarding activities or transactions involving parties located in Iran. The Company subsequently conducted an internal investigation under the direction of outside legal counsel and disclosed information concerning certain genomic testing services provided to an unrelated U.S.-based party engaged in veterinary activities involving an Iranian party. The Company continues to cooperate with OFAC’s investigation and is currently examining whether certain of these activities may be eligible for OFAC General Licenses authorizing agricultural and veterinary activities.

In addition to responding to the administrative subpoena, the Company ~~is implementing~~has implemented additional compliance measures to prevent inadvertent dealings with restricted countries or parties. These measures will further enhance the Company’s international trade compliance program, which is designed to assure that the Company does not conduct business directly or indirectly with any countries or parties subject to U.S. economic sanctions and export control laws. Although it is too early to predict what action, if any, that OFAC will take, the Company does not currently have any reason to believe that OFAC’s pending investigation will have a material impact on its operations, the results of operations for any future period, or its overall financial condition. In fiscal 2020, the Company took a charge to Other expense and recorded a reserve of ~~$600,000~~$

600,000 to provide for potential fines or penalties on this matter. At this time, the Company believes that it is adequately reserved for

this issue.

The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, should not have a material effect on its future results of operations or financial position.

. DERIVATIVES

We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates. and changes in interest rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, we enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions and have also entered into interest rate swap contracts as a hedge against changes in interest rates. All derivatives are recognized as assets or liabilities and measured at fair value. Derivatives that are not determined to be effective hedges are adjusted to fair value with a corresponding adjustment to earnings. We do not use financial instruments for trading or speculative purposes.

Derivatives Not Designated as Hedging Instruments

We forecast our net exposure in various receivables and payables to fluctuations in the value of various currencies, and have entered into a number of foreign currency forward contracts each month to mitigate that exposure. These contracts are recorded net at fair value on our consolidated balance sheets, classified as Level 2 in the fair value hierarchy; gains and losses from these contracts were recognized in other income in our consolidated statements of income (loss). The notional amount of forward contracts in place was $150.2 million and $4.4 million as of November 30, 2022 and May 31, 2022, respectively; the increase is the result of a number of intercompany loans entered into by our international operations as a result of the 3M Food Safety business combination.


(in thousands)
Fair Value of Derivatives Not Designated as Hedging Instruments	Balance Sheet Location	November 30, 2022			May 31, 2022
Foreign currency forward contracts, net	Other accruals	$	(9,708	)	$	(78	)

The location and amount of gains (losses) from derivatives not designated as hedging instruments in our consolidated statements of income (loss) were as follows:


		Three months ended
(in thousands) Derivatives Not Designated as Hedging Instruments	Location in statements of income (loss)	November 30, 2022			November 30, 2021
Foreign currency forward contracts	Other income (expense)	$	(9,128	)	$	492

		Six months ended
(in thousands) Derivatives Not Designated as Hedging Instruments	Location in statements of income (loss)	November 30, 2022			November 30, 2021
Foreign currency forward contracts	Other income (expense)	$	(8,248	)	$	1,011

Derivatives Designated as Hedging Instruments

In November 2022, we entered into a receive-variable, pay-fixed interest rate swap agreement designated as a cash flow hedge, which has a $250 million notional value. This agreement fixed a portion of the variable interest due on our term loan facility, with an effective date of December 2, 2022 and a maturity date of June 30, 2027. Under the terms of the agreement, we pay a fixed interest rate of 4.215% and receive a variable rate of interest based on term SOFR from the counterparty which is reset according to the duration of the SOFR term. The fair value of the interest rate swap as of November 30, 2022 was ($3.2) million.

We record the fair value of our interest rate swaps on a recurring basis using Level 2 observable market inputs for similar assets or liabilities in active markets.



(in thousands) Fair Value of Derivatives Designated as Hedging Instruments	Balance Sheet Location	November 30, 2022		May 31, 2022
Interest rate swaps – non-current	Other non-current liabilities	$	3,153	$	—

The impacts of our derivative instruments on the accompanying Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended November 30, 2022 and November 30, 2021 were as follows:


(in thousands)	Location in statements of comprehensive income (loss)	Three months ended				Six months ended
Derivatives Designated as Hedging Instruments	Location in statements of comprehensive income (loss)	November 30, 2022		November 30, 2021		November 30, 2022		November 30, 2021
Interest rate swaps	Unrealized gain/(loss) on derivative instruments, net of tax	$	(2,428)	$	—	$	(2,428)	$	—

PART I – FINANCIAL INFORMATION

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The information in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future financial performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial results.

Safe Harbor and Forward-Looking Statements

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form

10-Q.

For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, effects of the ongoing

COVID-19

pandemic on our business, global business disruption caused by the Russia invasion in Ukraine and related sanctions, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

In addition, any forward-looking statements represent management’s views only as of the day this Quarterly Report on Form

10-Q

was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.

~~COVID-19~~

TRENDS AND UNCERTAINTIES

During fiscal 2022 and the first six months of fiscal 2023, we have experienced higher than expected input cost inflation, including higher transportation, supply chain and labor costs, that have negatively impacted operating results. International freight costs, particularly for containers originating in Asia with an ultimate destination in the United States, have eased somewhat in the first half of fiscal 2023, although not to pre-2022 levels. Pricing actions taken during fiscal 2022 and the first six months of fiscal 2023 have mitigated some, but not all, of the inflationary pressures. Ongoing inflation may also have an impact on our customer’s purchasing decisions and order patterns. We estimate inflation will continue to affect us in the remainder of fiscal 2023, although at this time it is impracticable to quantify the impact.

Although we have no operations in or direct exposure to Russia, Belarus and Ukraine, we have experienced intermittent shortages in materials and increased costs for transportation, energy and raw materials due, in part, to the negative impact of the Russia-Ukraine military conflict on the global economy. To date, our European operations and customer base have not been materially impacted by the conflict, however, as the conflict continues or worsens, it may impact our business, financial condition or results of operations during the remainder of fiscal 2023.

As we ~~closely~~continue to monitor the

ongoing COVID-19

pandemic, our top priority remains protecting the health and safety of our ~~employees. While operations continue~~employees, their families, and those in our ~~locations around the world, many of our~~

~~non-manufacturing~~

~~and distribution employees continue to work remotely and travel remains limited.~~communities. Safety guidelines and procedures ~~including social distancing, mask wearing and enhanced cleaning, have been developed~~are in place for

on-site

employees and these policies are regularly monitored and updated by our internal Emergency Response Team.

~~In the first half of fiscal 2022, the~~

COVID-19

~~pandemic continued~~ continues to impact our business operations and financial results. A number of our ~~food safety diagnostic~~ product lines have been negatively impacted due to decreased demand in ~~many of~~ our customers’ businesses around the ~~world, particularly those serving restaurants, bars and other institutional food service markets.~~world. Many of our markets ~~across the world~~have recovered or are recovering, but the pandemic has continued to adversely impact our customers and ultimately, our revenues. We have also experienced supply chain difficulties directly related to COVID, including vendor disruptions, border closures, shipping issues and significantly increased shipping costs; labor shortages and higher labor costs, as we have had to use staffing agencies and increase our base pay in ~~many~~a number of areas of the ~~company~~Company to fill open ~~positions;~~positions and ~~restricted travel, which hinders our ability~~ to ~~connect with customers. During the current fiscal year, we have incurred less expense~~cover for ~~travel, meals, trade shows and some other customer-facing marketing activities; some of these activities have resumed but have not yet returned to~~COVID-related absences.

~~pre-pandemic~~

~~levels. Higher spend on shipping and labor are offsetting these savings.~~

Overall, the impact

of COVID-19 remains

uncertain and ultimately depends on the ~~length~~continued duration and severity of the pandemic, inclusive of the introduction of new strains of the virus; ~~the federal, state, and local~~ government actions taken in response; vaccination rates and effectiveness; the impact of vaccination requirements; extent of protection provided by prior viral infection; and the macroeconomic environment. We will continue to evaluate the nature and extent to

which COVID-19 ~~will~~

~~impact~~ has impacted our business, including supply chain, ~~including~~ labor availability and attrition, consolidated results of operations, financial condition, and liquidity; we expect it to continue to impact us through at least the end of our ~~current~~ fiscal ~~year.~~year ending May 31, 2023.

Executive Overview


	Three Months ended November 30,									Six Months ended November 30,
(in thousands)	2022			2021			%			2022			2021			%
Consolidated
Revenues	$	230,033		$	130,517			76	%	$	362,382		$	258,822			40	%
Core Sales Growth								7	%								5	%
Food Safety
Revenues	$	161,343		$	67,132			140	%	$	225,986		$	129,854			74	%
Core Sales Growth								6	%								6	%
Animal Safety
Revenues	$	68,690		$	63,385			8	%	$	136,396		$	128,968			6	%
Core Sales Growth								7	%								4	%
% of International Sales		50	%		41	%					46	%		40	%
Effective Tax Rate		n/a			16.2	%					n/a			19.5	%
Net Income (Loss)	$	(41,841	)	$	10,828			-486	%	$	(36,632	)	$	27,905			-231	%
Per Diluted Share	$	(0.19	)	$	0.10					$	(0.23	)	$	0.26
EBITDA*	$	12,639		$	18,533			-32	%	$	24,059		$	45,739			-47	%
Adjusted EBITDA*	$	64,051		$	29,594			116	%	$	91,070		$	58,490			56	%
Adjusted Net Income*	$	31,361		$	20,513			53	%	$	48,917		$	40,623			20	%
Cash (for) from Operations										$	(32,869	)	$	41,057

*	Refer to non-GAAP financial measures section in this document.

•

Food Safety core sales exclude revenues from the acquisitions of Delf/Abbott Analytical (November 2021) and Thai-Neo Biotech (July 2022) and also excludes the change in currency rates.

Food Safety revenues include $92.7 million from the 3M FSD, which we combined with on September 1, 2022. All of the global revenue from this business is reported within the Food Safety segment.

Animal Safety core sales exclude revenues from the acquisitions of CAPInnoVet (September 2021) and Genetic Veterinary Sciences (December 2021) and also excludes the change in currency rates.

•

Our net loss was $41.8 million, or ($0.19) per share, in the second quarter of fiscal 2023 compared to net income of $10.8 million, or $0.10 per share, in the second quarter of the prior year, adversely impacted by $39.1 million in legal, consulting and other expenses related to our combination with 3M’s Food Safety business. Year to date, our net loss was $36.6 million compared to income of $27.9 million in the prior year, adversely impacted by $52.9 million in legal, consulting and other expenses. Additionally, non-cash amortization and interest expense, both resulting from the 3M transaction, contributed to the net loss in the quarter and year to date periods.

~~Executive Overview~~

~~Consolidated revenues were $130.5 million~~

International sales rose 114% in the second quarter of fiscal 2022, an increase of 13% compared to $115.0 million in the second quarter of fiscal 2021. Organic sales growth in the second quarter of fiscal 2022 was 10%. For the six month period, consolidated revenues were $258.8 million, an increase of 15% compared to $224.3 million in the same period in the prior fiscal year. On a year to date basis, organic sales rose 12%.

Food Safety segment sales were $67.1 million in the second quarter of fiscal 2022, an increase of 17% compared to $57.5 million in the same period a year ago. Organic sales in this segment rose 11% for the comparative period, with revenues from the acquisition of Megazyme (December 2020) providing the remainder of the increase in revenues for the segment. For the year to date, Food Safety segment sales were $129.9 million, an increase of 16% compared to $111.7 million in the same period of the prior fiscal year; the organic sales increase was 10% for the comparative period, with the Megazyme acquisition providing the additional contribution to revenue.

Animal Safety segment sales were $63.4 million in the second quarter of fiscal 2022, an increase of 10% compared to $57.5 million in the second quarter of fiscal 2021. Organic sales in this segment also rose 10% in the second quarter, with a minor contribution from the CAPInnovet acquisition (September 2021). For the six month period, Animal Safety segment sales were $129.0 million, an increase of 15%, compared to $112.6 million in the same period a year ago. Year to date organic sales rose 14%, with revenues from the StandGuard (July 2020) and CAPInnovet acquisitions contributing the difference.

International sales in the second quarter of fiscal 2022 were 41% of total sales compared to 39% of total sales in the second quarter of fiscal 2021. For the year to date, fiscal 2022 international sales were 40% of total sales compared to 39% of total sales in the same period of the prior year.

Our effective tax rate in the second quarter was 16.2% compared to an effective tax rate of 17.8% in the prior year second quarter; the fiscal 2022 year to date effective tax rate was 19.5% compared to 18.9% for the same period a year ago.

Net income for the quarter ended November 30, 2021 was $10.8 million, or $0.10 per diluted share, compared to $15.9 million, or $0.15 per diluted share in the same period in the prior year. For the year to date, net income was $27.9 million, or $0.26 per diluted share compared to prior year to date net income of $31.7 million, or $0.30 per diluted share. Net income was decreased by $9.3 million of legal and consulting expenses for due diligence related to our recently announced agreement to combine with 3M’s Food Safety business.

~~Cash provided from operating activities in the first six months of fiscal 2022 was $41.1 million, compared to $47.5 million in the first half of fiscal 2021.~~

~~International sales rose 20% in both the second quarter of fiscal 2022~~2023 and also increased ~~20%~~60% for the year to date, each compared to the same respective periods in the prior year. ~~Excluding~~Revenues from the 3M FSD drove the international sales increase. In the second quarter of fiscal 2023, the ~~Megazyme acquisition, the increase~~FSD revenues were comprised of 66% international sales, compared to Neogen’s historical average of 40%.

Core growth, which excludes international revenues from FSD, Delf, Genetic Veterinary Sciences and Thai-Neo, and considers a neutral currency impact, was ~~14%~~6% for both the second quarter and year to date periods. The negative impact of currency, primarily from the stronger U.S. dollar against the pound, euro, Chinese yuan and Australian dollar for each comparative period, was $5 million in the second quarter and $8.9 million year to date. Revenue changes, expressed in percentages, for the three and six month periods of fiscal ~~2022~~2023 compared to the same ~~respective periods~~period in the prior year are as follows for the legacy business at each of our international locations:

Three Months Ended

Six Months Ended


November 30, 2021

November 30, 2021


Revenue

Revenue

Revenue

Revenue


% Inc (Dec)

% Inc (Dec)

% Inc (Dec)

% Inc (Dec)


USD

Local Currency

USD

Local Currency

U.K Operations (including Neogen Italia)
   20 % 14 % 13 % 6 %
Brazil Operations
   (5 )% (6 )% (10 )% (12 )%
Neogen Latinoamerica
   13 % 10 % 18 % 10 %
Neogen Argentina
   44 % 84 % 28 % 68 %
Neogen Uruguay
   (4 )% (2 )% 3 % 5 %
Neogen Chile
   48 % 54 % 59 % 59 %
Neogen China
   28 % 22 % 42 % 34 %
Neogen India
   (10 )% (9 )% 1 % 1 %
Neogen Canada
   34 % 28 % 60 % 50 %
Neogen Australasia
   29 % 27 % 38 % 33 %

~~Currency translations~~


	Three Months Ended November 30, 2022						Six Months Ended November 30, 2022
	Revenue % Inc (Dec) USD			Revenue % Inc (Dec) Local Currency			Revenue % Inc (Dec) USD			Revenue % Inc (Dec) Local Currency
U.K. Operations (including Neogen Italia)		(8	)%		9	%		(2	)%		14	%
Megazyme		(7	)%		8	%		(10	)%		4	%
Brazil Operations		21	%		16	%		17	%		15	%
Neogen Latinoamerica		5	%		1	%		11	%		10	%
Neogen Argentina		21	%		85	%		27	%		82	%
Neogen Uruguay		(11	)%		(17	)%		(6	)%		(13	)%
Neogen Chile		4	%		20	%		0	%		18	%
Neogen China		(9	)%		1	%		(14	)%		(7	)%
Neogen India		9	%		20	%		17	%		27	%
Neogen Canada		4	%		12	%		(2	)%		4	%
Neogen Australasia		(4	)%		7	%		(6	)%		3	%

In local currency, combined revenues at our U.K. operations increased ~~comparative revenues~~9% in the second quarter and 14% year to date, each compared to the same periods in the prior year. Excluding the December 2021 acquisition of Delf (UK), sales at our U.K. operations increased 2% in local currency in the second quarter and 7% for the year to date. Sales of food quality products at Megazyme, located in Ireland, increased 8% in local currency driven by ~~approximately $1.0~~increased volume and a significant research project.

Sales in Brazil increased 16% in local currency in this year’s second quarter and 15% year to date, driven by strong sales of the company’s mycotoxin test kits, including tests to detect aflatoxin in corn and deoxynivalenol (DON) in wheat, as well as increases in veterinary instruments, insect and rodent controls products, and genomics testing. Neogen Latinoamerica sales rose 1% in local currency for the second quarter and 10% year to date, with increases across the company’s diagnostic testing portfolio and culture media partially offset by lower cleaner & disinfectant sales in the second quarter, due to order timing from a large distributor. Sales at Neogen China increased 1% in local currency for the three month period but declined 7% for the year to date. A significant order of cleaners and disinfectants in the second quarter, in advance of Chinese New Year, offset declines in other product lines as the country’s COVID-19 related lockdowns continued to negatively impact sales for the respective periods. Revenues at Neogen’s Australasia operations increased 7% and 3% for the three and six month periods as bovine genomic service increases.were partially offset by a large non-recurring culture media order in the prior year.

Service revenue, which includes genomics testing and other laboratory services, was $26.7 million in the second quarter of fiscal 2023, an increase of 9% over the prior year second quarter revenues of $24.4 million. Excluding the contribution from the December 2021 acquisition of Genetic Veterinary Sciences and negative currency impact, global genomics service revenue increased 8% in the second quarter. For the six month period, service revenue was $52.3 million, an increase of 7% over prior year revenues of $48.7 million. Strong sales of our Neogen Analytics software as a service (SaaS) product and growth in the beef markets in the U.S. and Brazil for genomics testing was partially offset by COVID-related shutdowns in China, lower genomics sales to the porcine market, as a significant customer shifted to a lower-cost competitor, and a difficult comparison due to a large domestic research project recorded in the prior year which did not repeat.

Revenues


	Three Months Ended November 30,
(in thousands)	2022		2021		Increase/ (Decrease)			%
Food Safety
Natural Toxins, Allergens & Drug Residues	$	22,251	$	21,028	$	1,223			6	%
Bacterial & General Sanitation		41,121		12,252		28,869			236	%
Culture Media & Other		82,084		19,935		62,149			312	%
Rodent Control, Insect Control & Disinfectants		10,377		8,232		2,145			26	%
Genomics Services		5,510		5,685		(175	)		(3	)%

		161,343		67,132		94,211			140	%

Animal Safety
Life Sciences	$	1,427	$	1,309	$	118			9	%
Veterinary Instruments & Disposables		16,433		15,572		861			6	%
Animal Care & Other		10,569		10,849		(280	)		(3	)%
Rodent Control, Insect Control & Disinfectants		20,665		18,269		2,396			13	%
Genomics Services		19,596		17,386		2,210			13	%

		68,690		63,385		5,305			8	%

Total Revenues	$	230,033	$	130,517	$	99,516			76	%


	Six Months Ended November 30,
(in thousands)	2022		2021		Increase/ (Decrease)			%
Food Safety
Natural Toxins, Allergens & Drug Residues	$	42,038	$	41,432	$	606			1	%
Bacterial & General Sanitation		51,849		23,421		28,428			121	%
Culture Media & Other		101,338		37,981		63,357			167	%
Rodent Control, Insect Control & Disinfectants		19,952		15,882		4,070			26	%
Genomics Services		10,809		11,138		(329	)		(3	)%

		225,986		129,854		96,132			74	%

Animal Safety
Life Sciences	$	3,016	$	2,672	$	344			13	%
Veterinary Instruments & Disposables		31,106		30,909		197			1	%
Animal Care & Other		21,095		20,068		1,027			5	%
Rodent Control, Insect Control & Disinfectants		42,879		40,418		2,461			6	%
Genomics Services		38,300		34,901		3,399			10	%

		136,396		128,968		7,428			6	%

Total Revenues	$	362,382	$	258,822	$	103,560			40	%

Food Safety

3M’s former Food Safety business (“FSD”), which combined with Neogen on September 1, 2022, consists of five major product lines: indicator organisms (Petrifilm), general sanitation, sample handling, pathogen detection test kits and ~~$3.3 million~~allergen test kits. All of the global FSD business is currently being reported in Neogen’s Food Safety segment.

Natural Toxins, Allergens & Drug Residues – Sales in this category increased 6% and 1% for the three and six month periods ended November 30, 2022, compared to the same period in the prior year. Excluding sales of the acquired allergen product line from 3M, sales in this category decreased 2% in the second quarter and 3% for the year to date, primarily due to a significant decline in sales of drug residue test kits to international dairy markets. Natural toxin detection kits rose 5% for the quarter and were up 4% for the year to date. The increases for both periods were due to strength in aflatoxin test kits resulting from outbreaks in domestic and international grain harvests, and increases in histamine test kits. Sales of our legacy allergen test kits were flat in the second quarter and decreased 5% for the six month period. This decline across the company’s allergen testing portfolio was caused by softening market conditions and supply disruptions for certain products.

Bacterial & General Sanitation – Revenues in this category increased 236% and 121% for the second quarter and for the year to date, each compared to the same periods ~~a year ago, primarily due to~~in the ~~increased strength~~prior year. Excluding the contribution of the ~~British pound~~Biotrace line of general sanitation products and ~~Mexican peso relative to~~ the ~~U.S. dollar. Combined revenues at our U.K. operations increased 20% in the second quarter; growth was led by strong cleaner and disinfectant~~pathogen test kit product line, both acquired from 3M, organic sales into Asia, as the African swine fever outbreak continues to drive demand, and new culture media business with commercial laboratories in the U.K. that have adopted our recently launched One Broth One Plate workflow. For the six month period, revenues at our U.K. operations increased 13% as a large

~~non-recurring~~

~~prior year shipment of hand sanitizers to the U.K. government’s health organization affected growth in the first quarter.~~

~~Sales in Brazil decreased 5%~~ in this year’s second quarter, as an extended drought led to a significantly reduced corn crop and the associated testing, resulting in a large decrease in sales of aflatoxin test kits. For the six month period, sales at our Brazilian operations decreased 10%, primarily due to the reduced aflatoxin test kit sales and a large

~~non-recurring~~

insecticide sale to a government health organization in the first quarter of the prior fiscal year. Neogen Latinoamerica sales rose 13% for the second quarter, primarily due to increases in natural toxins test kits, environmental sanitation, culture media and biosecurity products. Sales at Neogen China increased 28% and 42% for the three and six month periods, respectively, from new sales of Megazyme products and growth in genomics, as the commercial dairy, swine and sheep markets have increased sampling volumes. The Neogen Australasia location benefitted from increased genomics business with customers in the beef and sheep markets.

~~Service revenue, which includes genomics testing and other laboratory services, was $24.4 million~~category were flat in the second quarter ~~of fiscal 2022, an increase of 9% over prior year second quarter revenues of $22.5 million. For~~and declined 2% for the six month period, service revenue was $48.7 million, an increase of 11% over prior year revenues of $43.9 million. The growth for both the quarter and year to date periods was led by increases in revenues at our Australia, China, U.K., Brazil and Canada genomics operations; growth in our domestic operation was reduced by lower volumes of companion animal samples, the result of difficult comparison from large increases in the prior year.

~~Revenues~~

Three Months Ended November 30,


Increase/

(in thousands)

2021

2020

(Decrease)

%

Food Safety

Natural Toxins, Allergens & Drug Residues
   $ 21,028    $ 20,001    $ 1,027    5 %
Bacterial & General Sanitation
   12,252    11,235    1,017    9 %
Culture Media & Other
   19,935    14,215    5,720    40 %
Rodenticides, Insecticides & Disinfectants
   8,232    7,059    1,173    17 %
Genomics Services
   5,685    5,024    661    13 %







   $ 67,132    $ 57,534    $ 9,598    17 %
Animal Safety

Life Sciences
   $ 1,309    $ 1,398    $ (89 )    (6 )%
Veterinary Instruments & Disposables
   15,572    11,974    3,598    30 %
Animal Care & Other
   10,849    9,371    1,478    16 %
Rodenticides, Insecticides & Disinfectants
   18,269    18,471    (202 )    (1 )%
Genomics Services
   17,386    16,252    1,134    7 %







   $ 63,385    $ 57,466    $ 5,919    10 %







Total Revenues
   $ 130,517    $ 115,000    $ 15,517    13 %

Six Months Ended November 30,


Increase/

(in thousands)

2021

2020

(Decrease)

%

Food Safety

Natural Toxins, Allergens & Drug Residues
   $ 41,432    $ 39,016    $ 2,416    6 %
Bacterial & General Sanitation
   23,421    21,166    2,255    11 %
Culture Media & Other
   37,981    26,387    11,594    44 %
Rodenticides, Insecticides & Disinfectants
   15,882    15,888    (6 )    0 %
Genomics Services
   11,138    9,262    1,876    20 %







   $ 129,854    $ 111,719    $ 18,135    16 %
Animal Safety

Life Sciences
   $ 2,672    $ 2,723    $ (51 )    (2 )%
Veterinary Instruments & Disposables
   30,909    22,349    8,560    38 %
Animal Care & Other
   20,068    17,029    3,039    18 %
Rodenticides, Insecticides & Disinfectants
   40,418    38,385    2,033    5 %
Genomics Services
   34,901    32,120    2,781    9 %







   $ 128,968    $ 112,606    $ 16,362    15 %







Total Revenues
   $ 258,822    $ 224,325    $ 34,497    15 %

~~Food Safety~~

~~Natural Toxins, Allergens~~

~~& Drug Residues –~~

~~Sales in this category increased 5% and 6% for the three and six month periods ended November 30, 2021, respectively,~~months, each compared to the same ~~periods~~period in the prior year. In the second quarter, an increase in sales of filters and ampoule media to beverage manufacturers and a 5% increase in sales of our ~~natural toxin test kits rose 10% as higher sales in the domestic pet food market and Europe~~AccuPoint line of general sanitation products were ~~partially~~ offset by lower ~~aflatoxin sales in Brazil, as a drought significantly reduced crop size and associated testing. Sales of allergen test kits rose 6% in the second quarter, while~~ sales of ~~our drug residue test kits declined 23% due~~Soleris^® equipment and consumables as worsening global economic conditions caused customers to ~~the termination of a European distribution agreement~~delay capital purchases and ~~competitive pressure within the marketplace.~~

~~Bacterial~~

~~& General Sanitation –~~

Revenues in this category increased 9% and 11% for the second quarter and for the year to date, compared to the same periods in the prior year. In the second quarter, sales of products to detect spoilage organisms in processed foods increased 22%, resulting from sales of our new instrument which continued to gain market acceptance after launching over a year ago. Sales of our AccuPoint sanitation monitoring product line increased 8% in the second quarter as strong sales of our new reader partially offset lower sales of consumables due to supply issues. Sales of products to detect pathogens increased 3% in the second quarter.

reduce sampling volumes.

Culture Media

& Other –

Sales in this category increased ~~40%~~312% in the quarter ended November 30, ~~2021~~2022 compared to the second quarter in the prior year; for the six month period, sales increased ~~44%~~167%. Excluding sales of the Petrifilm indicator organism and sampling handling product lines acquired from 3M, sales were flat in the ~~December 2020 acquisition~~second quarter and increased 3% for the year to date. Within this category, sales of ~~Megazyme, Veterinary~~our Neogen Analytics software as a service platform increased significantly, with approximately 175 sites now on contract. Additionally, an 11% increase in sales of culture media products in the second quarter, primarily due to a large sale to a vaccine manufacturer, was offset by a decline in food quality test kits, which ~~are reported~~was negatively impacted by currency.

Rodent Control, Insect Control & Disinfectants – Revenues in this category ~~sales~~ increased ~~17% and 19%~~26% for both the three and six month ~~periods, respectively. This~~periods; excluding the revenue contribution from the Delf acquisition in this category, ~~includes sales of instruments and other veterinary products at some of our international locations; these sales increased significantly over~~ the ~~prior year due to recovering markets and expanded market share. Sales of Neogen Culture Media products increased~~overall increase was 11% in the second quarter ~~as our new workflow, One Broth One Plate, continued~~and 10% for the year to ~~drive increased sales to commercial labs in the U.K.; the growth was partially offset by a decline in domestic sales due to~~

~~non-recurring~~

business in the prior year. For the six month period, Neogen Culture Media sales increased 22%, due to strength in the U.K. and also a large domestic sale to a vaccine manufacturer in the first quarter.

~~Rodenticides, Insecticides~~

~~& Disinfectants –~~

~~Revenues in this category increased 17%~~date. The increase in the second quarter ~~of fiscal 2022 compared~~was due to ~~the same period~~ a ~~year ago, due primarily~~large insect control order to ~~continued strength~~a government agency in Brazil and a significant order of cleaners and disinfectants ~~into Asia resulting from increased demand from the African swine fever outbreak~~to China in ~~that region; there was also higher sales~~advance of ~~rodenticides in Mexico. For the year to date, sales were flat, with the previously discussed increases being offset by large~~

~~non-recurring~~

~~sales of hand sanitizers in the U.K. and insecticides in Brazil in the first quarter of the prior fiscal year.~~

Chinese New Year.

Genomics Services –

Sales of genomics services sold through our international Food Safety operations ~~increased 13% and 20%~~decreased 3% for both the three and six month periods ended November 30, ~~2021, respectively. The increase~~2022. For each comparative period, unfavorable currency comparisons in the ~~second quarter was from overall strength at our labs~~U.K. and COVID-related lab closures in ~~the U.K., Brazil and~~ China ~~as improved economic conditions~~offset increased beef business in ~~several markets have contributed to increased testing.~~

Brazil.

Animal Safety

Life Sciences –

Sales in this category ~~decreased 6%~~increased 9% in the second quarter compared to the same period in the prior year; for the year to date, the ~~decrease~~increase in this product line was 2%13%. The ~~decline in~~increase for both comparative periods was due ~~primarily~~ to ~~the loss of hair~~higher demand from customers purchasing substrates and reagents used in clinical diagnostic test kits, and increased demand from forensic toxicology lab customers due to their higher testing ~~business with a large U.S. commercial laboratory that moved to a different testing platform.~~

volumes.

Veterinary Instruments

& Disposables –

Revenues in this category increased ~~30%~~6% and 1% for the three month period ended November 30, 2021, led by a large increase sales of in veterinary instruments, including needles and syringes, resulting from recently won private label business; revenues increased 38% for the year to date.

~~Animal Care~~

~~& Other –~~

~~Sales of these products increased 16% and 18% in~~ the three and six month periods ended November 30, ~~2021,~~2022, respectively. For the second quarter, disposable product sales increased significantly, as new products were added by a large retail customer. Additionally, sales of veterinary instruments increased 4% off a strong prior year comparison; sales of these products were 35% higher than sales in the second quarter of fiscal 2021. For the year to date period, veterinary instrument sales were up 1%, again due to a difficult prior year comparison.

Animal Care & Other – Sales of these products decreased 3% in the second quarter; year to date sales increased 5%. Excluding the contribution of parasiticides from the September 2021 acquisition of ~~CAPInnovet,~~CAPInnoVet, revenues increased 2% for the six month period. Within this category, sales of animal care products were flat in the second quarter, as increases in parasiticides and our Botulism B vaccine for horses were offset by declines in vitamin injectables and wound care products.

Rodent Control, Insect Control & Disinfectants – Revenues increased 13% and 6% for the three and six month periods ended November 30, 2022, each compared to the same period in the prior year. In the second quarter, sales of cleaners and disinfectants increased 26%, with new business earned in the animal protein market and strong sales of dairy hygiene products. Insect control products rose 13% in the quarter and rodenticide sales increased 6%. For the year to date, increases in cleaners and disinfectants and insect control product lines were partially offset by a decline in sales of rodent control products in the first quarter of fiscal 2023.

Genomics Services – Sales in this category increased 13% ~~in the second quarter, primarily due to strength in equine~~ and ~~companion animal markets. Additionally, we continued to regain customers with our recently~~

~~re-launched~~

~~ThyroKare~~

™

product. Partially offsetting these gains was a decline in sales of dairy supplies of 67% and 76% for the quarter and year to date periods, respectively, due to the June 2020 termination of an agreement in which we distributed these types of products for a large manufacturer of dairy equipment.

~~Rodenticides, Insecticides~~

~~& Disinfectants –~~

~~Revenues in this category decreased 1% for the three month period ended November 30, 2021, resulting from a 14% decrease in rodenticide sales due to supply constraints and a~~

~~non-outbreak~~

~~year. Insecticide sales rose 46% in the quarter, led by growth in the StandGuard~~

~~product line acquired in July 2020. Cleaners and disinfectants sales decreased 2% due to a difficult prior year comparison that included a large~~

~~non-recurring~~

~~sale. Sales of these products for the year to date period increased 5%, as compared to a year ago, for the same reasons.~~

~~Genomics Services –~~

~~Sales in this category increased 7% and 9%~~10% in the second quarter and the year to date periods, each compared to the prior ~~year. The growth~~year; excluding the contribution from Genetic Veterinary Sciences, revenues increased 4% in the second quarter and 1% for the year to date. For both periods, ~~was led by~~domestic increases in the beef ~~and sheep testing~~market were partially offset by unfavorable currency comparisons in Australia, ~~due to improved market conditions and higher~~lower sample volumes from ~~domestic dairy~~a large customer in the porcine market and ~~beef cattle and poultry customers. Growth in both the three and six month periods was partially offset by lower domestic companion animal revenues due to~~a difficult prior year ~~comparisons.~~

comparison due to a large research project which did not recur.

Gross Margin

Gross margin, expressed as a percentage of sales, was ~~46.4%~~48.9% in the second quarter of fiscal ~~2022~~2023 compared to ~~46.3%~~46.4% in the same quarter a year ago. The ~~slight change in~~increase was primarily due to the incremental revenues from the FSD merger, which generated gross margin ~~percentage is~~higher than the ~~result~~legacy company average margin. The legacy Neogen Food Safety business recorded a gross margin improvement of 280 basis points compared to the same quarter a ~~30 basis point improvement in Food~~year ago, while Animal Safety gross margins ~~partially offset by a 20~~increased 140 basis ~~point decline in gross margin percentage in~~points, each due primarily to pricing actions taken within the Animal Safety segment. The primary driver of the improved Food Safety gross margin percentage was incremental revenue from the Megazyme product line; these products generate higher gross margins than the average in this segment. In the Animal Safety segment, the slight decline in gross margin percentage was the result of lower sales of higher margin rodenticide products due to a lessening of vole pressure across the domestic market, and a reduction in genomics service revenues in the domestic companion animal markets.past 12 months. Within each segment, ~~higher~~increased raw material ~~and~~costs continued to pressure gross margins in certain product lines; however, freight in costs resulting from continued supply chain issues across most of our markets, put downward pressure on gross margins. The company has taken pricing actions where appropriate in response to these cost increases.dropped significantly during the comparative period, although they remained higher than pre-pandemic levels. For the year to date, gross margin was ~~46.6%~~48.2% compared to ~~46.1%~~46.6% in the prior year, ~~for~~primarily the ~~same reasons.~~

result of the higher gross margins from the FSD product lines, and pricing actions taken in the legacy Neogen Food and Animal Safety product lines.

Operating Expenses

Operating expenses were ~~$48.1~~$120.2 million in the second quarter of fiscal 2023, compared to ~~$34.0~~$48.1 million in the same quarter of the prior ~~year, an increase of $14.2 million, or 42%.~~year. Legal, consulting and other professional fees and expenses totaling ~~$9.3~~$39.1 million were incurred in the second quarter of the current fiscal year related to our combination with the 3M FSD, which closed on September 1, 2022. In the prior fiscal year second quarter, $9.3 million in ~~conjunction with due diligence~~deal costs relating to this transaction were incurred. In addition to the deal costs incurred in the current quarter, the Company recorded $20.3 million in amortization expenses relating to the intangible assets acquired in the merger, and ~~negotiation of terms~~$16.8 million in compensation and related expenses for the ~~proposed business combination with 3M’s Food Safety business, which was announced on December 14, 2021.~~conveyed employees. Excluding costs related to the transaction and the absorbed business, run rate operating expenses for the legacy business for the second quarter were ~~$38.8~~$44.4 million, an increase of ~~14%~~$5.6 million compared to $38.8 million in the prior year. Operating expenses for businesses acquired in the past year, excluding the FSD business, totaled $1.5 million and represented 27% of the increase in operating expenses for the second quarter of fiscal 2023.

For the six month period ended November 30, ~~2021, excluding~~2022, operating expenses of $176.4 million included $52.9 million in deal costs relating to the combination with the 3M FSD, $20.3 million in amortization of intangible assets acquired in the FSD merger, and $16.3 million in compensation and related operating expenses for the conveyed FSD employees. Run rate operating expenses for the legacy operating business were $86.9 million, an increase of $9.8 million, or 13% over the same period in the prior year, after adjusting for $9.3 million in deal costs incurred. Operating expenses for businesses acquired in the past year, excluding the FSD business, totaled $3.6 million and represented 37% of the increase in operating expenses ~~were $77.1 million, an increase~~for the first half of ~~18% compared to the prior year.~~

fiscal 2023.

Sales and marketing expenses ~~increased $3.5~~were $36.3 million ~~or 20%,~~ in the second quarter of fiscal 2023, compared to $21.2 million in last year’s second quarter. The increase in expense was due primarily to $12.9 million in compensation and related expenses for the conveying FSD sales and marketing team, effective September 1, 2022. Included in those expenses were amounts for transition services provided by 3M for invoicing and distribution. These costs will be provided under contract for a period of up to 18 months. The remainder of the increase for the quarter was due primarily to ~~increases in~~higher personnel related ~~expenses,~~spending in the legacy business, the result of ~~higher sales volumes~~headcount additions and ~~headcount. Additionally,~~compensation increases. In addition, travel, trade shows and other customer facing activities have continued to ~~rise,~~increase with the ~~result of~~ easing of ~~restrictions in a number of our markets due to the~~

COVID-19

~~pandemic; for~~ restrictions. For the year to date, sales and marketing expenses ~~increased 22% compared to~~were $59.7 million, an increase of $18.0 million over the same period last ~~year.~~year; the increase was driven by $12.9 million in absorbed expenses from personnel conveying in the FSD transaction, and increased travel, trade shows and other customer facing activities. Sales and marketing expenses from other acquired businesses were $600,000 and $1.5 million for the three and six month periods, respectively.

General and administrative ~~expense increased $10.4~~expenses were $77.0 million in the second quarter ~~primarily the result~~ of ~~$9.3~~fiscal 2023, and included $39.1 million in legal, consulting and other professional fees ~~resulting from due diligence efforts~~ and ~~negotiation of terms relating to the proposed transaction with 3M referenced above. Run rate general~~expenses and administrative expenses rose $1.1 million, or 9%, due primarily to increases in salaries and bonuses resulting from improved operating performance and additional senior management hires, higher amortization expenses from the Megazyme and CAPInnovet acquisitions, increased stock based compensation expense and higher depreciation and license fees relating to information technology infrastructure and software. These increases were partially offset by $1$20.3 million in ~~spending~~amortization for intangible assets acquired in our combination with the 3M FSD, which closed on ~~strategic consulting, legal~~September 1, 2022. After adjusting for these deal-related expenses, and ~~other professional fees related to acquisition activity~~an additional $1.4 million in incremental expenses incurred in absorbing the ~~prior year~~business into Neogen, second quarter ~~for businesses which we were not ultimately successful in acquiring. Year to date,~~ run rate general and administrative expenses were $16.2 million, an increase of $2.9 million, or 22%, compared to the same period a year ago. The increase was primarily the result of additional personnel hired to accommodate the increased ~~15%,~~size and complexity of the organization, compensation increases across the organization, including at the senior leadership level, the issuance of share based compensation grants, license fees and other information technology infrastructure investments and $800,000 in incremental operating expenses from our other recent acquisitions, including amortization of intangible assets acquired. For the year to date, after adjusting for the $52.9 million in deal costs resulting from the combination with the 3M FSD and $20.3 million in amortization of intangibles acquired in the FSD merger, run rate general and administrative expenses were $31.7 million, an increase of $5.0 million compared to the same ~~reasons.~~

period a year ago. General and administrative expenses from recent acquisitions, excluding the 3M FSD combination, were $1.3 million of the increase.

Research and development expense was ~~$4.3~~$6.8 million in the second quarter of fiscal 2023, an increase of ~~$270,000,~~$2.5 million, or 7%58%, compared to the same period in the prior year. The increase was primarily the result of ~~incremental costs~~$2.0 million of ~~personnel absorbed from~~cost associated with the ~~Megazyme acquisition~~conveying FSD employees, and outside ~~service~~testing and validation costs for new commercial products under development ~~spending on new products.~~in the Animal Safety segment. For the year to date, research and development expenses ~~increased 9% over~~were $11.7 million compared to $8.7 million in the same period last year, with the increase due primarily to the $2.0 million in conveying FSD personnel and testing and validation for new commercial products in the ~~same reasons.~~

Animal Safety segment.

Operating Income

~~Operating income~~ (Loss)

The operating loss was ~~$12.5~~$7.7 million in the second quarter of fiscal ~~2022,~~2023, compared to ~~$19.2~~operating income of $12.5 million in the same period of the prior ~~year;~~year. For the year to date period, the operating ~~income~~loss was ~~$34.2~~$1.6 million compared to ~~$38.1~~operating income of $34.2 million in the prior year. Expressed as a percentage of sales, the operating ~~income~~loss was ~~9.6%~~3.3% for the second quarter and ~~13.2%~~0.4% for the year to date, compared to ~~16.7%~~income of 9.6% and ~~17.0%~~13.2%, respectively, for the same periods in the prior year. Adjusting for the ~~$9.3~~$39.1 million in transaction costs resulting from the ~~proposed~~ 3M transaction ~~operating income was 16.7%~~ in the second quarter, and ~~16.8%~~$52.9 million of these costs for the year to ~~date.~~

~~Other Income~~

Three Months Ended

Six Months Ended


November 30,

November 30,

(dollars in thousands)

2021

2020

2021

2020

Interest income (net of expense)
   $ 217    $ 555    $ 420    $ 1,277
Foreign currency transactions
   167    (432 )    15    (256 )
Insurance settlement
   —      309    —      —
Legal settlement
   —      (300 )    —      —
LGS contingent consideration
   (135 )    —      (135 )    —
Other
   210    (42 )    141    (16 )








Total Other Income
   $ 459    $ 90    $ 441    $ 1,005

~~The decrease in interest~~date period, operating income was $31.4 million, or 13.7% in the second quarter and $51.3 million, or 14.2% for the year to date. After adjusting out $9.3 million in deal costs incurred in both the second quarter and year to date periods in fiscal 2022, prior year operating income for those periods was $21.8 million, or 16.7%, and $43.5 million, or 16.8%. The primary reason for the lower operating income percentage in each comparative period was the amortization of the intangible assets acquired in conjunction with the FSD merger.

Other Income


	Three Months Ended						Six Months Ended
	November 30,						November 30,
(dollars in thousands)	2022			2021			2022			2021
Interest income	$	553		$	246		$	1,523		$	455
Interest expense		(20,545	)		(22	)		(20,547	)		(28	)
Foreign currency transactions		(6,108	)		167			(6,530	)		15
LGS contingent consideration		—			(135	)		—			(135	)
Other		(335	)		203			(284	)		134

Total Other Income	$	(26,435	)	$	459		$	(25,838	)	$	441

The net interest expense incurred for the three and six month ~~period of fiscal~~periods ended November 30, 2022 ~~compared to the same period a year ago~~ was the result of ~~continued lower yields~~the $1 billion in debt incurred to fund the 3M FSD combination. In fiscal 2022, the Company had no debt outstanding, and interest income relates to earnings on our marketable securities ~~balances.~~portfolio. Other income or expense resulting from foreign currency transactions was the result of changes in the value of foreign currencies relative to the U.S. dollar in countries in which we ~~operate. In~~operate; the increase in expense for the second quarter and year to date periods in fiscal 2023 was due to U.S. dollar denominated loans incurred in our international subsidiaries as the result of the ~~current fiscal year, we recorded a charge of $135,000 for additional contingent consideration in the final payment to the former owner of Livestock Genomic Services.~~FSD transaction on September 1, 2022.

Income Tax Expense

Income tax expense in the second quarter of fiscal ~~2022~~2023 was ~~$2.1~~$7.8 million, ~~an effective tax rate of 16.2%,~~ compared to ~~$3.5~~$2.1 million ~~an effective tax rate of 17.8%,~~ in the same period of the prior ~~year. For~~year; for the year to date, income tax expense was $9.2 million, compared to $6.8 million ~~an effective rate of 19.5%,~~ in fiscal 2022 and $7.4 million, an effective rate of 18.9%, in fiscal 2021. For each period, the primary difference between the statutory rate of 21% and the effective rates recorded is the benefit resulting from the exercise of stock options; this benefit was $859,0002022. Income tax expense in the second quarter of fiscal ~~2022 compared~~2023 includes approximately $6.7 million of expense related to ~~$1,060,000~~non-deductible transaction costs associated with the 3M FSD transaction and $625,000 of expense due to an increase in our deferred tax liability rate. In each comparative period, there was minimal benefit from the ~~second quarter~~exercise of ~~the prior year. For the year to date, the benefit was $874,000 in fiscal 2022 compared to $1,481,000 in fiscal 2021.~~ stock options.

The ~~decrease in~~total amounts of unrecognized tax benefits that, if recognized, would affect the effective tax rate ~~for the second quarter was primarily due to lower taxable income resulting from fees related to the 3M combination.~~as of November 30, 2022 and May 31, 2022 are $1.4 million and $808,000, respectively. The increase in ~~effective rate~~unrecognized tax benefits is primarily associated with the combined 3M FSD, including positions for ~~the year to date period is the result~~transfer pricing and research and development credits.

Net Income

The Company incurred a net loss of lower benefit from stock option exercises and a $548,000 charge to expense in the first quarter because the U.K. enacted a higher tax rate effective in 2023. Since our deferred tax balances at this operation are expected to reverse in the future at the higher tax rate, we were required to revalue them when the new rate was passed.

~~Net Income~~

~~Net income was $10.9~~$41.8 million in the second quarter of fiscal ~~2022,~~2023, compared to ~~$15.9~~net income of $10.8 million in the same period in the prior year. The decline in earnings for ~~this year’s second~~the quarter was primarily the result of ~~$9.3~~$39.1 million in legal, consulting, professional fees and other ~~professional fees~~expenses from the ~~intended~~3M FSD transaction, ~~with 3M. Excluding those charges, net income rose 14%~~$20.0 million interest expense from the $1 billion in debt incurred in the ~~second quarter of fiscal 2021 compared to~~merger, and $20.3 million in incremental amortization expenses associated with the ~~same period~~intangible assets acquired in the ~~prior year.~~merger. For the year to date, the Company incurred a net ~~income was $27.9~~loss of $36.6 million, ~~a decrease of 12%~~ compared to ~~$31.7~~net earnings of $27.9 million in the prior ~~year; excluding the $9.3 million of expense, net income rose 11% year to date. Six~~year. Three and six month net income in fiscal ~~2022~~2023 was also negatively impacted by a higher effective tax rate.

Non-GAAP Financial Measures

This report includes certain financial information for the Company that differs from what is reported in accordance with GAAP. These non-GAAP financial measures consist of core revenue growth, EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Net Income and Adjusted Earnings per Share. These non-GAAP financial measures are included in this report because management believes that they provide investors with additional useful information to measure the performance of the Company, and because these non-GAAP financial measures are frequently used by securities analysts, investors and other interested parties as common performance measures to compare results or estimate valuations across companies in industries the Company operates in.

Core revenue growth

We define core revenue growth as net sales for the period excluding the impacts of foreign currency translation rates and the first year impacts of acquisitions and disposals, where applicable. We present core revenue growth because it allows for a meaningful comparison of results across periods without the volatility caused by foreign currency gains or losses, or the incomparability that would be caused by the impact of an acquisition or disposal.

EBITDA

We define EBITDA as net income before interest, income taxes, and depreciation and amortization. We present EBITDA as a performance measure because it may allow for a comparison of results across periods and results across companies in the industries in which Neogen operates on a consistent basis, by removing the effects on operating performance of (a) capital structure (such as the varying levels of interest expense and interest income), (b) asset base and capital investment cycle (such as depreciation and amortization) and (c) items largely outside the control of management (such as income taxes). EBITDA also forms the basis for the measurement of Adjusted EBITDA (discussed below).

Adjusted EBITDA

We define Adjusted EBITDA as EBITDA, adjusted for share-based compensation and certain transaction fees and expenses. We present EBITDA because it provides an understanding of underlying business performance by excluding the following:

•

Share-based compensation. We believe it is useful to exclude share-based compensation to better understand the long-term performance of our core business and to facilitate comparison with the results of peer companies.

•

Other income/(expense). We exclude items in other income/(expense), which consists of primarily foreign currency transactions and, to a lesser extent, one-time amounts unrelated to our core business, to better understand the long-term performance of our core business.

•

Certain transaction fees and expenses. We exclude fees and expenses related to certain transactions because they are outside of Neogen’s underlying core performance. These fees and expenses include deal related professional and legal fees and foreign currency transactions.

•

Other one-time adjustments. We exclude one-time adjustments recorded within operating income to better understand the long-term performance of our core business.

Adjusted EBITDA margin

We define Adjusted EBITDA margin as Adjusted EBITDA as a percentage of total revenues. We present Adjusted EBITDA margin as a performance measure to analyze the level of Adjusted EBITDA generated from total revenue.

Adjusted Net Income

We define Adjusted Net Income as Net Income, adjusted for share-based compensation, other income/(expense), certain transaction fees and expenses, and other one-time adjustments, all of which are tax effected.

Adjusted Earnings per Share

We define Adjusted Earnings per Share as Adjusted Net Income divided by diluted average shares outstanding.

These non-GAAP financial measures are presented for informational purposes only. EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Net Income and Adjusted Earnings per Share are not recognized terms under GAAP and should not be considered in isolation or as a substitute for, or superior to, net income (loss), operating income, cash flow from operating activities or other measures of financial performance. This information does not purport to represent the results Neogen would have achieved had any of the transactions for which an adjustment is made occurred at the beginning of the periods presented or as of the dates indicated. This information is inherently subject to risks and uncertainties. It may not give an accurate or complete picture of Neogen’s financial condition or results of operations for the periods presented and should not be relied upon when making an investment decision.

The use of the terms EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Net Income and Adjusted Earnings per Share may not be comparable to similarly titled measures used by other companies or persons due to potential differences in the method of calculation.

These non-GAAP financial measures have limitations as analytical tools. For example, for EBITDA-based metrics:

they do not reflect changes in, or cash requirements for, Neogen’s working capital needs;

they do not reflect Neogen’s tax expense or the cash requirements to pay taxes;

they do not reflect the historical cash expenditures or future requirements for capital expenditures or contractual commitments;

they do not reflect any cash requirements for future replacements of assets that are being depreciated and amortized; and

they may be calculated differently from other companies in Neogen’s industries limiting their usefulness as comparative measures.

You should compensate for these limitations by relying primarily on the financial statements of Neogen and using these non-GAAP financial measures only as a supplement to evaluate Neogen’s performance.

For each of these non-GAAP financial measures below, we are providing a reconciliation of the differences between the non-GAAP measure and the most directly comparable GAAP measure.

Reconciliation between net income and EBITDA and Adjusted EBITDA and between net income margin % and Adjusted EBITDA margin % are as follows:


	Three Months Ended November 30						Six Months Ended November 30
(dollars in thousands)	2022			2021			2022			2021
Net Income (Loss)	$	(41,841	)	$	10,828		$	(36,632	)	$	27,905
Net income margin %		-18.2	%		8.3	%		-10.1	%		10.8	%
Provision for income taxes		7,750			2,100			9,200			6,750
Depreciation and amortization		26,738			5,829			32,467			11,511
Interest income, net		19,992			(224	)		19,024			(427	)

EBITDA	$	12,639		$	18,533		$	24,059		$	45,739
Share-based compensation		2,632			1,748			4,499			3,438
FX transaction loss on loan revaluation⁽¹⁾		5,789			—			5,789			—
Certain transaction fees and expenses		39,132			9,313			52,864			9,313
Inventory step-up charge		3,859			—			3,859			—

Adjusted EBITDA	$	64,051		$	29,594		$	91,070		$	58,490

Adjusted EBITDA margin %		27.8	%		22.7	%		25.1	%		22.6	%

⁽¹⁾

Net foreign currency transaction loss associated with the revaluation of non-functional currency intercompany loans established in connection with 3M Food Safety transaction.

Adjusted EBITDA increased $35.3 million and $33.6 million for the three and six month periods, respectively, due to earnings generated from the 3M FSD business, which merged with Neogen on September 1, 2022. Expressed as a percentage of revenue, adjusted EBITDA was 28.1% for the second quarter of fiscal 2023 compared to 23.1% for the same period last year, and was 25.4% for the six month period. The 3M FSD business was not part of the Company in the prior six month period; thus, the adjusted EBITDA amount for that period is not directly comparable.

Reconciliation between net income and Adjusted Net Income and earnings per share and Adjusted Earnings per Share are as follows:



	Three months ended November 30						Six Months Ended November 30
(in thousands, except for percentages)	2022			2021			2022			2021
Net Income (Loss)	$	(41,841	)	$	10,828		$	(36,632	)	$	27,905
Earnings per share	$	(0.19	)	$	0.10		$	(0.23	)	$	0.26
Amortization of acquisition-related intangibles		22,116			1,770			23,957			3,455
Share-based compensation		2,632			1,748			4,499			3,438
FX transaction loss on loan revaluation⁽¹⁾		5,789			—			5,789			—
Certain transaction fees and expenses		39,132			9,313			52,864			9,313
Inventory step-up charge		3,859			—			3,859			—
Other adjustments⁽²⁾		4,350			—			4,350			—
Estimated tax effect of above adjustments⁽³⁾		(4,676	)		(3,146	)		(9,769	)		(3,488	)

Adjusted Net Income	$	31,361		$	20,513		$	48,917		$	40,623

Adjusted Earnings per Share	$	0.15		$	0.19		$	0.30		$	0.38

⁽¹⁾

Net foreign currency transaction loss associated with the revaluation of non-functional currency intercompany loans established in connection with the 3M FSD transaction.

⁽²⁾

Income tax expense associated with non-deductible transaction costs that were recognized as expense in prior periods.

⁽³⁾

Tax effect of adjustments is calculated using projected effective tax rates for each applicable item.

Adjusted Net Income increased $10.8 million and $8.3 million for the three and six month periods, respectively, due to the higher Adjusted EBITDA partially offset by interest expense.

Financial Condition and Liquidity

The overall cash, cash equivalents and marketable securities position of Neogen was ~~$389.2~~$276.3 million at November 30, ~~2021,~~2022, compared to $381.1 million at May 31, ~~2021. Approximately $41.1~~2022. Cash flow from operating activities was negative $32.9 million ~~was generated from operations~~ during the first six months of fiscal ~~2022~~2023, the result of 3M FSD deal-related expenses, and ~~spent $26.9 million on acquisitions.~~inventory increases. Net cash proceeds of ~~$6.6 million~~$920,000 were realized from the exercise of stock options and issuance of shares under our Employee Stock Purchase Plan during the first six months of fiscal ~~2022.~~2023. The Company paid down $60 million in principal on the term loan during the second quarter. We spent ~~$5.2~~$25.1 million for property, equipment and other

non-current

assets in the first ~~half~~six months of the fiscal ~~2022.~~

year, with spending of $3.4 million on our ERP implementation of SAP, $2.4 million on construction of our Lansing manufacturing facility, and approximately $400,000 in IT for laptops and software for the conveying employees related to the FSD business.

Net accounts receivable balances were ~~$92.5~~$142.7 million at November 30, ~~2021, an increase of $700,000,~~2022 compared to ~~$91.8~~$99.7 million at May 31, ~~2021.~~2022. Days’ sales outstanding, a measurement of the time it takes to collect receivables, were 54 days for the legacy Neogen business at November 30, 2022, compared to 62 days at May 31, 2022 and 63 days at November 30, ~~2021, compared~~2021. As part of transition services agreements between the Company and 3M, related to ~~66 days at May 31, 2021~~the merger of the Food Safety business, 3M is invoicing our customers for products that 3M is manufacturing and ~~61 days at~~shipping on our behalf. At November 30, ~~2020. We have been carefully monitoring our~~2022, there are $46.3 million in customer receivables asbilled by 3M on our behalf. The Company is working collaboratively with 3M on managing the

~~COVID-19~~

~~pandemic has spread across our global markets;~~ credit risk associated with the former FSD customers during the period when 3M is providing transition invoicing and distribution services to the Company. To date, we have not experienced an appreciable increase in bad debt write ~~offs.~~

offs related to the ongoing COVID-19 pandemic.

Net inventory was ~~$107.1~~$136.1 million at November 30, ~~2021,~~2022, an increase of ~~$6.4~~$13.8 million, compared to a May 31, ~~2021~~2022 balance of ~~$100.7~~$122.3 million. The ~~two acquisitions completed in~~higher inventory levels are primarily the result of continued inflationary pressures on raw materials at our legacy businesses and raw material inventories purchased to support the combined 3M FSD. Supply chain issues moderated somewhat during the second quarter ~~added approximately $1.0 million to our inventory balance. Additionally,~~of fiscal 2023; we have been increasing inventory levels recently in an effort to reduce freight costs and prevent backorders, as shipments are taking longer and some suppliers are requiring higher orders due to their supply constraints.

~~Inflation and changing prices are not expected to have a material effect on operations, as management believes it will~~ continue to ~~be successful~~monitor our key raw materials to ensure adequate stock on hand.

Debt and Liquidity

On September 1, 2022, Neogen, 3M, and Garden SpinCo, a newly formed subsidiary of 3M created to carve out 3M’s Food Safety business, closed on the transaction which had previously been announced in ~~offsetting increased input costs~~December 2021, combining 3M’s Food Safety business with ~~price increases and/or cost efficiencies.~~Neogen in a Reverse Morris Trust transaction.

~~Management believes that our existing cash~~

On June 30, 2022, Garden SpinCo entered into a credit agreement consisting of a five-year senior secured term loan facility in the amount of $650 million and ~~marketable securities balances at November 30, 2021, along~~a five-year senior secured revolving facility in the amount of $150 million (collectively, the “Credit Facilities”), which became available in connection with ~~available borrowings under our credit~~the merger and related transactions. The loan facility was funded to Garden SpinCo on August 31, 2022, and ~~cash expected~~upon the effectiveness of the merger on September 1, 2022, became Neogen’s obligation. Financial covenants include maintaining specified levels of funded debt to ~~be generated from operations, will be sufficient to fund activities~~EBITDA, and debt service coverage. Pricing for the ~~remainder~~term loan is term SOFR plus 235 basis points. The Credit Facilities, together with the Notes below, represent the financing incurred in connection with the merger of the ~~current fiscal year. However,~~3M FSD with Neogen. On September 30, 2022, the Company paid down $60 million in principal on the term loan.

In July 2022 Garden SpinCo closed on an offering of $350 million aggregate principal amount of 8.625% senior notes due 2030 (the “Notes”) in a private placement at par. The Notes were initially issued by Garden SpinCo to 3M and were transferred and delivered by 3M to the selling securityholder in the offering, in satisfaction of certain of 3M’s existing debt. Garden SpinCo did not receive any proceeds from the sale of the Notes by the selling securityholder. Prior to the distribution of the shares of Garden SpinCo’s common stock to 3M stockholders, the Notes were guaranteed on a senior unsecured basis by 3M. Upon consummation of such distribution, 3M was released from all obligations under its guarantee. Upon the effectiveness of the merger on September 1, 2022, the Notes became guaranteed on a senior unsecured basis by Neogen and certain wholly-owned domestic subsidiaries of Neogen.

In addition to the 3M transaction described above, our future cash generation and borrowing capacity ~~will~~may not be ~~insufficient~~sufficient to meet cash requirements to fund the operating business, repay debt obligations, construct new manufacturing facilities, commercialize products currently under development or execute our future plans to acquire additional businesses, technology and products that fit within our strategic plan. Accordingly, we may be required, or may choose, to issue additional equity securities or enter into other financing arrangements for a portion of our ~~planned combination with the 3M Food Safety business, which~~future capital needs; there is ~~currently expected to close in the third quarter of calendar year 2022. The transaction~~no guarantee that we will be ~~funded by~~successful in issuing additional equity securities ~~to 3M’s shareholders and borrowing approximately $1 billion in cash under an agreement with JPMorgan Chase.~~or entering into other financing arrangements.

PART I – FINANCIAL INFORMATION

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We have interest rate and foreign exchange rate risk exposure but no long-term fixed rate investments or borrowings. Our primary interest rate risk is due to potential fluctuations of interest rates for short-term investments.

Foreign exchange risk exposure arises because we market and sell our products throughout the world. Revenues in certain foreign countries as well as certain expenses related to those revenues are transacted in currencies other than the U.S. dollar. Our operating results are exposed to changes in exchange rates between the U.S. dollar and the British pound sterling, euro, Mexican peso, Brazilian real, Chinese yuan, Australian dollar and to a lesser extent, the Thai baht, Japanese yen, South Korean won, Indian rupee, Canadian dollar, Guatemalan quetzal, Argentine peso, Uruguayan peso and Chilean peso; there is also exposure to a change in exchange rate between the British pound sterling and the euro. When the U.S. dollar weakens against foreign currencies, the dollar value of revenues denominated in foreign currencies increases. When the U.S. dollar strengthens, the opposite situation occurs. Additionally, previously invoiced amounts can be positively or negatively affected by changes in exchange rates in the course of collection.

We use derivative financial instruments to help manage the economic impact of fluctuations in certain currency exchange rates. These contracts are adjusted to fair value through earnings.

Neogen has assets, liabilities and operations outside of the U.S., located in Scotland, England, Ireland, Italy, Switzerland, Poland, Brazil, Mexico, Guatemala, Argentina, Uruguay, Chile, China, Thailand, Japan, Korea, India, Canada and Australia where the functional currency is the British pound sterling, euro, Brazilian real, Mexican peso, Guatemalan quetzal, Argentine peso, Uruguayan peso, Chilean peso, Chinese yuan, Thai baht, Japanese yen, South Korean won, Indian rupee, Canadian dollar and Australian dollar, respectively. Our investments in foreign subsidiaries are considered long-term. As discussed in ITEM 1A. RISK FACTORS of our Annual Report on Form 10-K for the ~~Form~~

~~10-K~~

~~annual filing,~~year ended May 31, 2022, our financial condition and results of operations could be adversely affected by currency fluctuations.

The following table sets forth the potential loss in future earnings or fair values, resulting from hypothetical changes in relevant market rates or prices:

Risk Category

Hypothetical Change

November 30, 2021

Impact

(dollars in thousands)

Foreign Currency - Revenue
   10% Decrease in exchange rates    $ 5,414    Earnings
Foreign Currency - Hedges
   10% Decrease in exchange rates    1,959    Earnings


Risk Category	Hypothetical Change	November 30, 2022		Impact
(dollars in thousands)
Foreign Currency—Revenue	10% Decrease in exchange rates		$ 46,248	Earnings
Foreign Currency—Hedges	10% Decrease in exchange rates		15,021	Fair Value
Interest Income	10% Decrease in interest rates		127	Earnings
Interest Expense	10% Increase in interest rates		2,068	Earnings

PART I – FINANCIAL INFORMATION

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of November 30, ~~2021~~2022 was carried out under the supervision and with the participation of the Company’s management, including the President & Chief Executive Officer and the Vice President & Chief Financial Officer (“the Certifying Officers”). Based on the evaluation, the Certifying Officers concluded that the Company’s disclosure controls and procedures are effective.

Changes in Internal Controls over Financial Reporting

No changes in our control over financial reporting were identified as having occurred during the quarter ended November 30, ~~2021~~2022 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

~~The Company~~

For a description of our material pending legal proceedings, see Note 12 “Commitments and Contingencies” of the Notes to interim consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is ~~subject to legal and other proceedings~~incorporated by reference.

Item 1A.

Risk Factors

This Form 10-Q should be read in conjunction with Part I Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended May 31, 2022. There have been no material changes in the ~~normal course of business. In~~risk factors described in our Annual Report on Form 10-K for the ~~opinion of management, the outcomes of these matters~~year ended May 31, 2022.

Items 2, 3, 4, and 5 are not ~~expected to~~applicable or removed or reserved and have ~~a material effect on the Company’s future results of operations or financial position.~~been omitted.

Item

6. Exhibits

(a) Exhibit Index


2.1		Agreement and Plan of Merger, dated as of December 13, 2021, by and among 3M Company, Garden SpinCo Corporation, Neogen Corporation and Nova RMT Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).

2.2		Separation and Distribution Agreement, dated as of December 13, 2021, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).

2.3		Amendment No. 1 to the Separation and Distribution Agreement, dated as of August 31, 2022, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

2.4		Asset Purchase Agreement, dated as of December 13, 2021, by and between 3M Company and Neogen Corporation (incorporated by reference to Exhibit 2.3 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).

3.1		Certificate of Amendment to Articles of Incorporation filed on October 11, 2010 (incorporated by reference to Exhibit 3.2 filed with the Registrant’s Annual Report on Form 10-K filed on July 30, 2020).

3.2		Restated Articles of Incorporation, as amended on November 23, 2011 (incorporated by reference to Exhibit 3.1 filed with the Registrant’s Quarterly Report on Form 10-Q filed December 30, 2011).

3.3		Certificate of Amendment to Articles of Incorporation filed on November 20, 2018 (incorporated by reference to Exhibit 3 filed with the Registrant’s Quarterly Report on Form 10-Q filed December 28, 2018).

3.4		Certificate of Amendment to Articles of Incorporation of Neogen Corporation filed on March 14, 2022 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by Neogen Corporation on March 17, 2022).

3.5		Certificate of Amendment to Articles of Incorporation of Neogen Corporation filed on September 1, 2022 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

3.6		By-Laws, as amended (incorporated by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q filed April 14, 2000).

3.7		Amendment to the By-Laws, as amended (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

4.1		Senior Notes Indenture for 8.625% Senior Notes due 2030, dated as of July 20, 2022, among Garden SpinCo Corporation, as issuer, the guarantors party thereto from time to time, and U.S. Bank Trust Company, National Association, as trustee (incorporated by reference to Exhibit 10.10 to Neogen’s Registration Statement on Form S-4 (Registration No. 333-263667), filed with the SEC on July 27, 2022).

4.2		Supplemental Indenture, dated as of September 1, 2022, among Neogen Food Safety Corporation (f/k/a Garden SpinCo Corporation), as issuer, U.S. Bank Trust Company, National Association, as trustee, Neogen Corporation and certain of its subsidiaries (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

10.1		Tax Matters Agreement, dated as of September 1, 2022, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

10.2		Intellectual Property Cross-License Agreement, dated as of September 1, 2022, by and between 3M Company and Garden SpinCo Corporation (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

10.3		Trademark Transitional License Agreement, dated as of September 1, 2022, by and among 3M Company, 3M Innovative Properties Company, Neogen Corporation and Garden SpinCo Corporation (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

10.4		Transition Services Agreement, dated as of September 1, 2022, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

10.5		Transition Distribution Services Agreement, dated as of September 1, 2022, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

10.6		Transition Contract Manufacturing Agreement, dated as of September 1, 2022, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

10.7		Clean-Trace(TM) Distribution Agreement, dated as of September 1, 2022, by and between 3M Company and Garden SpinCo Corporation (incorporated by reference to Exhibit 10.7 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

10.8		Real Estate License Agreement, dated as of September 1, 2022, by and among certain subsidiaries of Neogen Corporation, 3M Company and certain of its subsidiaries (incorporated by reference to Exhibit 10.8 to the Current Report on Form 8-K filed by Neogen Corporation on September 1, 2022).

10.9		Credit Agreement, dated as of June 30, 2022, among Garden SpinCo Corporation, as borrower, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, and joined thereto as of September 1, 2022 by Neogen Corporation, as a borrower (incorporated by reference to Exhibit 10.9 to Neogen’s Registration Statement on Form S-4 (Registration No. 333-263667), filed with the SEC on July 27, 2022).

31.1		Certification of Principal Executive Officer

31.2		Certification of Principal Financial Officer

32		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

~~Items 1A, 2, 3, 4, and 5 are not applicable or removed or reserved and have been omitted.~~

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NEOGEN CORPORATION

(Registrant)

Dated: ~~December 30, 2021~~

January 9, 2023

/s/ John E. Adent

John E. Adent

President & Chief Executive Officer

(Principal Executive Officer)

Dated: ~~December 30, 2021~~

January 9, 2023

/s/ Steven J. Quinlan

Steven J. Quinlan

Vice President & Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)


				Weighted-
				Average
(Options in thousands)	Shares			Exercise Price
Options outstanding June 1, 2021		2,957		$	30.38
Granted		392			40.93
Exercised		(262	)		22.42
Forfeited		(21	)		31.11

Options outstanding November 30, 2021		3,066		$	32.40


	Three Months Ended						Six Months Ended
	November 30, 2021						November 30, 2021
	Revenue			Revenue			Revenue			Revenue
	% Inc (Dec)			% Inc (Dec)			% Inc (Dec)			% Inc (Dec)
	USD			Local Currency			USD			Local Currency
U.K Operations (including Neogen Italia)		20	%		14	%		13	%		6	%
Brazil Operations		(5	)%		(6	)%		(10	)%		(12	)%
Neogen Latinoamerica		13	%		10	%		18	%		10	%
Neogen Argentina		44	%		84	%		28	%		68	%
Neogen Uruguay		(4	)%		(2	)%		3	%		5	%
Neogen Chile		48	%		54	%		59	%		59	%
Neogen China		28	%		22	%		42	%		34	%
Neogen India		(10	)%		(9	)%		1	%		1	%
Neogen Canada		34	%		28	%		60	%		50	%
Neogen Australasia		29	%		27	%		38	%		33	%


	Three Months Ended November 30,
					Increase/
(in thousands)	2021		2020		(Decrease)			%
Food Safety
Natural Toxins, Allergens & Drug Residues	$	21,028	$	20,001	$	1,027			5	%
Bacterial & General Sanitation		12,252		11,235		1,017			9	%
Culture Media & Other		19,935		14,215		5,720			40	%
Rodenticides, Insecticides & Disinfectants		8,232		7,059		1,173			17	%
Genomics Services		5,685		5,024		661			13	%

	$	67,132	$	57,534	$	9,598			17	%
Animal Safety
Life Sciences	$	1,309	$	1,398	$	(89	)		(6	)%
Veterinary Instruments & Disposables		15,572		11,974		3,598			30	%
Animal Care & Other		10,849		9,371		1,478			16	%
Rodenticides, Insecticides & Disinfectants		18,269		18,471		(202	)		(1	)%
Genomics Services		17,386		16,252		1,134			7	%

	$	63,385	$	57,466	$	5,919			10	%

Total Revenues	$	130,517	$	115,000	$	15,517			13	%